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ABSTRACT
A necessary first step in modeling the metabolic reaction network is a systematic 
procedure for determining the different reaction sequences which connect two 
metabolites. A software system (MPS) has been designed on the principles of artificial 
intelligence in order to address the problem of analysis and synthesis of metabolic 
pathways leading from one carbon-containing metabolite to another. MPS can be used to 
predict on a qualitative basis the effects of adding or deleting enzymatic activities to or 
from the cellular environment, to extract information about metabolic regulation, and to 
direct experiments in metabolic engineering. The main principles that have been used for 
the development of MPS are described along with case studies demonstrating the 
capabilities and potential applications of such a software system. The examples will 
examine carbon catabolic pathways and amino acid biosynthetic pathways. The catabolic 
pathways example concentrates on the conversion of glucose 6-phosphate to pyruvate. 
The output from MPS, which synthesized the classical catabolic pathways along with 
possible variations, leads to the identification of required genotypes/sets of enzymes that 
convert glucose 6-phosphate to pyruvate with different ATP and NAD(P)H coupling. 
The amino acid examples refer to the production of L-alanine from pyruvate and the 
identification of alternative pathways that perform this bioconversion.
The appropriate use of controllable promoters and plasmid origins of replication 
provide an opportunity for identifying operating strategies that maximize productivity of 
unstable recombinant cultures. This is demonstrated by first developing a kinetic model 
for product formation in recombinant cultures that exhibit both segregational and 
structural instability, and subsequently by identifying operating conditions that maximize 
productivity with respect to the base case (uncontrollable promoter and plasmid origin of 
replication).
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Finally, an approach is being made to examine the validity of traditional-macroscopic 
relationships for the description of equilibrium cellular processes. A model is described 
that addresses these processes from a statistical point of view and results of this model 
are compared with analogous results obtained from traditional methods applied to a 
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FIGURE 1.1: The part of the metabolic chart related to glucose 6-phosphate catabolism. 
FIGURE 1.2: Two of the pathways produced by MPS for the conversion of glucose 6-
phosphate to pyruvate. Pathway 4 has been identified as the pentose phosphate 
pathway and pathway 9 as the Embden-Meyerhof-Pamas pathway.
FIGURE 1.3: Schematic representation of the Embden-Meyerhof-Pamas pathway. 
FIGURE 1.4: Schematic representation of the pentose phosphate pathway.
FIGURE 1.5: Schematic representation of a variation of the pentose phosphate pathway. 
FIGURE 1.6: A variation of the pentose phosphate pathway that leads to the concurrent
production of pyruvate and erythrose 4-phosphate.
FIGURE 1.7: The schematic representation of a pathway in which substances assume a
pseudocatalytic role.
FIGURE 1.8: The schematic representation of two pathways leading from pyruvate to 
L-alanine.
FIGURE 1.9: One of the four pathways that MPS synthesized for the conversion of 
pyruvate to L-alanine.
FIGURE 1.10: The schematic representation of the pathway show in Figure 9.
FIGURE 2.1: Schematic diagram of basic functional elements in an expression plasmid
(A) and diagram of genetic transitions in a recombinant population with structural 
and/or segregational instability (B).
FIGURE 2.2: Alternate forms of the protein synthesis rate function f [Eq. (9.1)] consid­
ered in these models.
FIGURE 2.3: Simulated batch bioreactor trajectories for pure segregational instability 
(0=0; φ=0.01) without product inhibition (n=0).
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FIGURE 2.4: Calculated productive cell fraction ψ and product concentration after sub 
strate exhaustion in a batch bioreactor as a function of cell plasmid content (pure 
segregational instability; θ=0, φ=0.01, without product inhibition; n=0. Calcula­
tions for ∕(μ) given by Eq. 2.30 (∙), Eq. 2.31 (0), and Eq. 2.29 (o)).
FIGURE 2.5: Dependence of final product content and productive cell fraction after 
substrate exhaustion in a batch bioreactor for different instability and product in­
hibition models. Solid symbols correspond to inhibition based on intracellular 
product concentration (Model I), and open symbols correspond to Model ∏ which 
employs overall broth product concentration to evaluate product inhibition. Cir­
cles are for pure structural instability (θ=0.01, φ=0), and squares were calculated 
for pure segregational instability (θ=0, φ=0.01). ∕(μ) given by Eq. 2.29 for all
cases.
FIGURE 2.6: Simulated final productive cell fraction and product concentration versus 
the gene expression parameter, γ, characteristic transcription and translational ef­
ficiency, for product inhibition Model I (∙) and Model ∏ (o). (φ=0.01, θ=0, 
Np=50)
FIGURE 2.7: Computed time trajectories of total cell concentration and productive cell 
fraction following initiation of continuous-flow bioreactor operation. Dilution 
rates shown: D=0.1, 0.2, 0.3, 0.4, 0.5, 0.6, and 0.7 hr -1. (φ=0.01, θ=0, product 
inhibition Model I, Eq. 2.29 for ∕(μ).)
FIGURE 2.8: Experimentally measured interferon activity obtained from recombinant 
E.coli fermentation as a function of inducer (nalidixic acid) concentration. In­
ducer concentration is correlated with cloned-gene transcriptional activity (data 
from Ref. 43 of Chapter 2).
FIGURE 3.1: Diagram of the assumed trajectories for cellular plasmid content and gene 
expression parameter following a switch to environmental conditions promoting 
amplification and gene expression at time tχMP or tεχp, respectively.
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FIGURE 3.2: (A) Final cloned-gene product concentration (grams protein/liter culture) 
vs. the switching time (the time of plasmid amplification (o) and time of cloned- 
gene induction (∙)). (B) Fraction of cells containing plasmids after substrate ex­
haustion in the batch process as a function of initiation times for amplification (o) 
or gene expression (∙).
FIGURE 3.3: Illustration of product concentration at substrate exhaustion as a function 
of the time of amplification (îamp) and the time of expression (îexp) when both 
events can be activated independently at different points during batch operation. 
For the particular parameters considered here, maximum product accumulation is 
provided for tAMp=10, tEχp=10, Npχmal=50, γf=1.0.
FIGURE 3.4: Final productive cell fraction vs. amplification and expression switching 
times for batch operation. Same parameters as Fig. 3.3.
FIGURE 3.5: Time trajectories (solid lines) of the productive cell fraction and cloned- 
gene product concentration vs. operating time in a batch reactor with ϊαμρ=10, 
tEXP=10. Shown for comparison (dashed lines) are trajectories for the uncontrolled 
case with Np=50, γ=1.0.
FIGURE 3.6: Final product and productive cell fraction values for different induced 
gene expression activity values γ as a function of induction time tEXP; batch 
reactor.
FIGURE 3.7: Calculated final product concentration vs. amplification initiation switch­
ing time for negligible product inhibition (o: Np,finaι=50j ·: Np,fi∏aι=9θ5 
Δ: Np final=120).
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FIGURE 3.8: Simulated effluent product concentration and productive cell fraction for 
three different CSTR reactor cascades. Values are shown as functions of time 
since startup. Conditions in tanks 1, 2, and 3 favor cell growth, cause plasmid 
amplification, and induce gene expression, respectively. Different symbols corre­
spond to different V]:V2:V3 tank volume ratios. o=l:l:l; ·=1:1.5:3; Δ=3:1.5:1.
FIGURE 4.1: The results of the statistical (points) and the traditional (lines) approaches 
for equilibrium calculations for the lac repressor-operator system. Here 
[0]o=l molecule/cell.
FIGURE 4.2: Equilibrium concentrations calculated for the lac repressor-operator sys­
tem based on the statistical (points) and the traditional (lines) approaches. In this 
case [O]0=15 molecules/cell.
FIGURE 4.3: The relative error [(Otrad-Ostat)∕Ostat] associated with the use of the tradi­
tional single-cell intracellular equilibrium relations for the calculation of the ratio 
[O]∕[O]0∙
FIGURE Al: The general representation of enzymes in the data base.
FIGURE A2: The representation of homoserine acyltransferase and phosphogfycero- 
mutase in the enzyme data base.
FIGURE A3: The representation of 3-phospho-D-glyceroyl phosphate and O-phospho- 
L-homoserine in the substance data base.
FIGURE A4: A simple search network.
FIGURE A5: Reaction networks incorporate multiple linear pathways in order to pro­
vide the necessary substances for reactions requiring more than one reactant.
FIGURE A6: Reaction networks incorporate cyclic pathways when substances that have 
been already consumed are regenerated.
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The advent of genetic engineering technology has provided an array of techniques and 
methods that can be used to genetically modify microorganisms in order to biologically 
produce bioproducts of interest. These modifications, however, introduce an unnecessary 
and unnatural burden to the host cell. The host organism is not evolutionarily optimized 
towards the production of some bioproduct of interest to us, and having to use its 
enzymatic machinery to carry out the additional load of instructions (plasmid replication, 
foreign gene expression, etc.), its own growth and survival is inhibited. Therefore, most 
of the applications of recombinant DNA technology concentrate on the minimization of 
the interactions of the host cell with the additional artificially implanted plasmids or 
genes. This minimization hopefully leads to the minimization of the exhibited growth 
inhibition, providing a relatively healthy recombinant cell population that is capable of 
producing the bioproduct(s) of interest. The base level of interactions that a host 
organism can have with a plasmid constitutes of sharing its replication, transcription, and 
translation enzymatic sets to reproduce and express the plasmid and the genes on the 
plasmid. Therefore, an effort has been made in the past to identify host-vector systems in 
which the bioproduct of interest would be inactive within the host’s environment.
An inactive bioproduct would clearly provide a minimum level of interactions 
between the host cell and the plasmid. However, this approach is not always possible or 
justifiable. For some bioproducts it can be extremely hard to find an organism in which 
these substances are biologically inactive. If, for example, one wishes to genetically 
modify an organism in order to overproduce an amino acid, then, one cannot find a living 
organism in which a given amino acid is not biologically active. On the other hand, the 
activity of biomolecules, and especially the activity of polypeptides, depends not only on 
the chemical structure but also on the conformation and tertiary structure that has been 
attained. The biologically active conformation is by definition achieved in an 
environment that the molecule is active. Therefore, it is necessary to examine the
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possible interactions of a given bioproduct with the overall cellular function and 
especially with cellular metabolism.
The metabolic cellular network is an extensive and complex network reactions the 
majority of which cannot be kinetically analyzed with the ctπτent analytical techniques. 
A first approach to addressing this problem is to analyze the qualitative aspects of the 
metabolic network and examine the effects of possible addition to or deletion from the 
network of enzymatic activities. The motivation behind this approach is that metabolism 
has evolved to a network of reactions not by accident but by the necessity to offer to the 
living cell the adaptivity and flexibility required by life. The identification of the 
properties of the network, properties that can be derived by examining possible routes for 
the interconvertion of given metabolites to target metabolites, is an important a 
necessary step for modeling cellular metabolism. Such a step has been taken and is 
described in the first chapter of the thesis. The constructed algorithm (MPS) can help the 
biochemical engineer to decide about the required genotypes or organisms that will best 
serve to the overproduction of a metabolite of interest.
A second important decision process is that of identifying the operating conditions 
that would lead to the optimization of the productivity of recombinant DNA cultures. 
Given that the existence of a foreign plasmid inhibits the growth of the host cell, then if 
an instability on the plasmid reproduction can lead to the appearance of two populations 
one carrying the plasmid and one being the wild type, the wild type cells have a growth 
advantage over the plasmid carrying ones. This can under certain conditions lead to the 
extinction of the recombinant population. The scenario becomes even more unfavorable 
for the plasmid carrying cells if product inhibition is also considered. Product inhibition 
can be present both for a biologically inactive and a biologically active product. It can be 
safely assumed, though, that the latter case (biologically active substance) will lead to 
higher growth inhibition. In order to examine these phenomena, a kinetic model has been
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developed for product formation in unstable recombinant DNA populations. For the 
description of product formation the model is based on classical chemical engineering 
kinetics descriptions for the reactions characterizing gene expression. The full model and 
its development is described in the second chapter. In the third chapter the model is being 
used to derive optimal operating strategies that maximize productivity of both batch and 
continuous fermentors, based on the assertion that one can use controllable plasmid 
replicons and gene promoters.
Finally, cells are most of the time modeled as ideally stirred reactors (and this 
approach has been used for the development of the product formation model of chapter 
2). This cannot be always assumed as being a correct approach. Key biological 
substances exist in the cell in very small amounts (of the order of a few molecules per 
cell). It is, therefore, doubtful that traditional approaches involving macroscopic 
descriptions of such phenomena as reactions at equilibrium are valid for modeling 
molecular cellular processes. A more rigid approach would consist of a statistical 
description of the processes. That approach has been derived in chapter 4 for the 
characterization of reactions at equilibrium, and has been applied to a subset of the 
reactions that constitute the control mechanism of the lac operator-promoter. The results 
obtained are compared with the results of the traditional approach for the same system.
-5-
CHAPTER 1
MPS: AN ARTIFICIAL!- Y INTELLIGENT SOFTWARE SYSTEM 




The objective of metabolic engineering is to redirect cellular metabolism in order 
to achieve higher or lower yield or rate of formation of bioproducts. The decision of 
which microorganism and conditions to use is the primary problem faced by the bio­
chemical engineer. Different microorganisms incorporate different sets of enzymes 
for the degradation of nutrients and synthesis of bioproducts, and the same microor­
ganism uses different subsets of its enzymes in different media. Moreover, genetic 
engineering may be applied for modifying the metabolic reaction network employed 
by a cell. The ability to specifically mutate genes that code for enzymes offers the 
opportunity of removing enzymatic activity from the cellular environment. On the 
other hand, the advent of recombinant DNA technology provides the capability of 
introducing through plasmids new or supplemental quantities of existing enzymes 
or proteins that inhibit or amplify existing enzymatic activities. A systematic tool 
to predict the effects of such genetic modifications on the productivity of the desired 
compound can be very valuable in the design of optimal bioprocesses.
Cellular metabolism has, through evolution, developed into a large and complex 
reaction network. Through an extensive number of intermediates and allosteric 
enzymatic control mechanisms, the functional adaptivity and stability required by 
life is maintained. The ability of a bacterial cell to survive under a variety of envi­
ronmental conditions, and sometimes under major genetic modifications, is largely 
due to the flexibility of the metabolic reaction network to decrease or increase the 
rate of substrate consumption or product-intermediate formation. This freedom is 
expressed by choices among alternative pathways which, through different sets of re­
actions, utilize substrates, energy, and reducing power with different stoichiometric 
coupling, leading to different product, energy and reducing power yield factors.
The complexity of cellular metabolism and, mainly, the fact that the kinetic 
behavior of most of the enzymes is not accessible in vivo restrict the development 
of detailed models based on chemical engineering kinetics. Such models have been
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developed based on a small number of key enzymatic activities and are not easily 
expandable. 1, 2
In order to predict on a qualitative basis the effects of genetic modifications, 
such as deleting or adding enzymatic activities to a cell, a software system has been 
developed that synthesizes metabolic pathways. The system, called MPS, is based 
on the principles of artificial intelligence in order to analyze the metabolic network 
efficiently. MPS software embodies artificial intelligence concepts in the sense that 
a complicated search is conducted guided by rules embodied in the program to 
conduct the search efficiently. Solution of complex search problems is one of the 
major components of artificial intelligence research and application.3-17
Although MPS does include screening and pathways analysis features which aid 
the user to investigate and interpret information obtained from the set of pathways 
synthesized, it is not an “expert system” in the sense that it attempts to relieve 
the user of the responsibility for some knowledge and for applying at least modest 
levels of inductive and deductive reasoning. Thus, MPS is intended as a research 
and development tool to be used by those with a basic perspective on the purposes 
and strategies of metabolism.
MPS is designed to generate the pathways that convert a given substance to 
a target metabolite. It generates and reports only the genetically independent 
pathways, while at the same time the synthesis algorithm overcomes the cycles and 
other degeneracies existing in the metabolic network. Cyclic sequences of enzyme- 
catalyzed steps and the presence of multiple enzymatic activities that catalyze the 
same reaction are the major problems of analyzing the metabolic network through 
classical approaches, since they introduce singularities in the stoichiometric matrices 
used for such approaches. 18, 19
Artificial intelligence and graph theory concepts have been previously applied 
for different purposes in chemistry, 2θ and the potential for some applications of 
artificial intelligence in biotechnology has been discussed in recent articles. 21 ∙ 22 
Research has been conducted in the past for molecular representations and enu­
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meration of isomers, 23 for chemical documentation, 24 for representing chemical 
reactions, 25, 26 and for organic synthesis. 27, 28, 29 However, the problem of analyz­
ing the metabolic network is fundamentally different from any problem of organic 
synthesis. 30 The heuristics that organic chemists (and, therefore, artificially intel­
ligence programs that address the problem of organic synthesis) apply can not be 
used in the synthesis and analysis of metabolic pathways. The conversion of glucose 
to pyruvate, for example, can be performed in the laboratory environment in many 
different ways, but generally the actual set of reactions that has been chosen by 
living organisms (these will be presented in a later section of this paper) cannot 
be followed in vitro. These reactions are the only ones available within the cellular 
environment, and involve a set of intermediates, the importance of which is not 
clear when a given conversion is examined, but which is revealed when alternative 
pathways are also examined. Furthermore, the energetics of bioconversions are also 
important for metabolic pathways. For example, from a chemist’s point of view, 
the conversion of glucose to CO2 and H2O is a trivial procedure, while, from the 
cellular perspective, this oxidation involves both the pathways to pyruvate and the 
tricarboxylic acid cycle. The stoichiometry of ATP, NADH and NADPH produc­
tion by a cell oxidizing glucose can vary significantly, depending on the pathways 
employed.
THE DESIGN OF MPS
MPS consists of data bases for enzymes and substrates and a search and screen­
ing algorithm. MPS has been written in Common Lisp, 31 using a GCLISP LM 
interpreter and compiler on an IBM PC AT, eqquiped with 3.5Mb of CPU mem­
ory. MPS calls on two data bases, one which stores substances and the other which 
stores enzymes and characteristics of the corresponding enzyme-catalyzed reaction 
in vivo. Because of limited data on intracellular metabolite concentrations, Gibbs 
free energy changes associated with metabolic reactions in vivo are generally not
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available. Consequently, the enzyme data base in MPS categorizes the associated 
reaction either as reversible or as irreversible in vivo. Further details on the struc­
ture of these data bases, crucial to the efficient functioning of MPS, are provided in 
the Appendix.
The search algorithm has been designed to generate all the independent path­
ways of transforming a given intermediate to a given target substance. The defini­
tion of independency of pathways employed in MPS is illustrated by the following 
example: Consider the reaction network set:
E1 : A → B + C 
E2∙. B - C 
E3 : B → F 
Ei ∙. C → F
Given A to be the initial substance and F the target substance, how many inde­
pendent ways exist for the transformation of A to P? The description of pathways 
that is used by MPS consists of a series of enzyme nodes (enzyme ι∕), where v is 
the number of times the standard reaction catalyzed by enzyme participates in the 
pathway. Then the following pathways of converting A to F exist:
P1 ≡ (P1 l)(P2 1)(E4 2)
P2 ≡ (El l)(P2 -1)(F32)
P3 ≡ (E1 l)(Es 1)(P4 1)
The overall reaction for all three pathways is A → 2F. Are these three pathways 
independent? From a traditional point of view based on linear independence of the 
reactions, these are not independent since:
P3 = 0.5P1 + 0.5P2
However, if the question of independency is posed in the form: “Does each pathway 
shown define an independent genotype?”, then each of these three pathways is in­
deed independent. This is the way that MPS defines the independence of pathways.
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To reduce the computational effort and computer memory required to elaborate 
and store metabolic pathways, it is important to adopt efficient procedures for 
identifying routes to certain required enzyme co-substrates. These and other rules 
designed to streamline the combinatorial growth of an unwieldy set of expanding 
pathways are summarized and illustrated by example in the Appendix.
The search algorithm, when completed, returns the pathways performing the 
transformation of the initial substance to the target substance. The fact that LISP 
is very efficient in handling symbolic information is very helpful in order to identify 
subsets of the pathways that fullfil some property.In order to make the user-MPS 
interaction easier, a menu-driven program that performs screening of the pathways 
based on a limited number of criteria has also been incorporated in MPS. The 
criterion that the user may require for indentifying a subset of pathways of interest 
could be any combination of requirements that specified enzymes participate or 
not in the pathway, or for substances to be involved in the overall reaction of the 
pathway as substrates, as products, or not to be involved at all. Pathways can 
be displayed and stored through this additional screening program in a readable 
manner as will be shown in the examples that follow.
EXAMPLES OF USE OF MPS
In order to illustrate the performance of MPS, the conversion of glucose 6-phosphate 
to pyruvate and the conversion of pyruvate to alanine will be considered. The 
data base used was the full scale data base presently available to MPS. There are 
approximately 90 enzymes and 120 substances in the current enzyme and substance 
data bases.
1 GLUCOSE 6-PHOSPHATE TO PYRUVATE
The part of the metabolic chart related to the conversion of glucose 6-phosphate to 
pyruvate is shown in Figure 1.1.
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MPS constructed twenty independent pathways for converting glucose 6-phosphate 
to pyruvate. MPS synthesis of all of these took 46 seconds to be completed. Screen­
ing on the basis of no carbon-carrying by-products, except CO2, resulted in ten 
independent pathways. Information about these ten pathways can be found in Ta­
bles 1.1 (stoichiometry) and 1.2 (enzyme participation). The actual output from 
MPS for two pathways is shown in Figure 1.2. The information reported by MPS 
for each pathway consists of:
1. The set of enzymes that are involved in the pathway.
2. The number of times that the standard reaction for each enzyme stored in 
the data base is used by the pathway. In the case that a reversible reaction is 
used in a direction opposite direction from the one stored, a negative number 
is reported.
3. The overall reaction and stoichiometry of the pathway.
1.1 The Embden-Meyerhof-Parnas Family of Pathways
The most classical pathway for the catabolism of glucose 6-phosphate, the EMP 
pathway, is shown schematically in Figure 1.3. MPS reported the EMP as Pathway 
9 (Tables 1.1, 1.2 and Figure 1.2).
What other variations of this pathway have been generated by MPS? Observe 
that in Figure 1.1, there exists a way of converting dihydroxyacetone phosphate to 
pyruvate that does not involve glyceraldehyde 3-phosphate. This conversion is the 
methylglyoxal bypass. 32 Therefore, when fructose 1,6-biphosphate is converted to 
dihydroxyacetone phosphate and glyceraldehyde 3-phosphate, one option is to con­
vert the generated dihydroxyacetone phosphate to glyceraldehyde 3-phosphate for 
a yield of 2 moles of glyceraldehyde 3-phosphate per mole of glucose 6-phosphate 
consumed, and carry on with the conversion of glyceraldehyde 3-phosphate to pyru­
vate. This option generates the EMP pathway. A second option, though, is for the 
triosephosphate isomerase reaction to be followed in the opposite direction, i.e.
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glyceraldehyde 3-phosphate to be converted to dihydroxyacetone phosphate, and 
then the methylgyoxal bypass to be followed. This variation of the EMP pathway 
was reported by MPS (Pathway 10).
What happens if a microorganism is not capable of performing the triosephos- 
phate isomerase reaction (due to missing or inactivated enzyme)? Can pyruvate 
be produced via a variation of the EMP pathway and in a yield of two moles of 
pyruvate per mole of glucose 6-phosphate consumed? Provided that the enzymatic 
activities involved in the two branches originating from glyceraldehyde 3-phosphate 
and dihydroxyacetone phosphate, respectively, are present in the cell, then the an­
swer to this question is yes (Pathway 2). If, however, an enzyme in one of the two 
branches is missing, then this conversion is not possible. In that case one mole of 
pyruvate will be produced from one mole of glucose 6-phosphate, and one mole of 
one of the two triose phosphates will be a side product in the conversion. These 
pathways have been also reported by MPS. The MPS search algorithms carry out 
the logical decisions and branching summarized in the previous discussion without 
user intervention in order to determine the genetically independent pathways. These 
comments are intended to illustrate the types of logic which have been implemented 
in MPS in order to synthesize these pathways and those discussed below.
1.2 The Pentose Phosphate Family of Pathways
Next the pentose phosphate pathway, shown as Pathway 4 in Tables 1.1 and 1.2 
and Figure 1.2, and schematically in Figure 1.4, will be considered. One difference 
with the EMP family of pathways (2, 9 and 10) that can be immediately noticed is 
that NADPH, absent from the EMP overall reaction, is generated by the pentose 
phosphate pathway. A second evident difference is the pyruvate yield. The pro­
duction of CO2 that is involved in the pentose phosphate pathway leads to a lower 
pyruvate yield of less than two moles per mole of glucose 6-phosphate processed. 
Overall yields and stoichiometries are provided by MPS output; no user input or 
calculations are required to obtain these quantities.
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Since, as shown in Figure 1.4, the same structure for the glyceraldehyde 3- 
phosphate conversion to pyruvate that was seen in the EMP pathway is present 
in the pentose phosphate pathway, MPS has reported the variations involving the 
methylglyoxal bypass that were mentioned earlier (Pathways 1 and 3).
By comparing the enzymatic sets of the EMP pathway and the pentose phos­
phate pathway (Figure 1.2), we can see that all but the first enzyme of the EMP 
pathway, glucose phosphate isomerase, are involved in the pentose phosphate path­
way. What would happen if a cell did not have the ability to convert fructose 
6-phosphate to fructose 1,6-biphosphate? Clearly, all the pathways of the EMP 
family would be eliminated. What about the pentose phosphate pathway? Is there 
a variation of this pathway that will make the cell capable of producing pyruvate? 
Observe in Figure 1.4 that, at the point of the pentose phosphate pathway where 
fructose 6-phosphate has been generated, glyceraldehyde 3-phosphate has been gen­
erated as well. Two molecules of fructose 6-phosphate and one molecule of glyc­
eraldehyde 3-phosphate are produced from three molecules of glucose 6-phosphate. 
Then, a possible variation of this pathway is the following: two molecules of fruc­
tose 6-phosphate, instead of going through the EMP pathway, are recycled via the 
glucosephosphate isomerase to glucose 6-phosphate. MPS utilizes this logic. The 
overall stoichiometry incorporates the net consumption of one molecule of glucose 
6-phosphate and the net production of one molecule of glyceraldehyde 3-phosphate, 
which can be converted to pyruvate. This variation has been reported by MPS 
(Pathway 5), and is schematically shown in Figure 1.5. So it is possible for the 
cell to convert glucose 6-phosphate to pyruvate without possessing phosphofructok- 
inase, the enzyme which catalyzes the production of fructose 1,6-biphosphate. The 
methyglyoxal bypass variation of the pathway has been also reported (Pathway 6).
1.3 The Entner-Doudoroff Family of Pathways
The remaining pathways reported by MPS are the two variations of the ED pathway, 
one with the methy]gyoxal bypass (Pathway 8) and one without the methylglyoxal
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bypass (Pathway 7). Note that the ED family of pathways has a pyruvate yield of 
two moles per mole of glucose 6-phosphate (like the EMP family of pathways) and 
produces NADPH (like the pentose phosphate family of pathways).
Other information provided by MPS and the resulting pathways will next be 
examined. By inspection, it is easy to deduce what pathways are eliminated if one 
or more enzymes are deactivated by mutation. Consider Table 1.2, which has also 
been generated by MPS, and which refers to the ten pathways discussed earlier. 
Deletion of the enzyme gluconolactonase, for example, will lead to the elimination 
of pathways 1 and 3 through 8, and the resulting genotype will have the ability to 
convert glucose 6-phosphate to pyruvate and no metabolites as by-products only via 
pathways 2, 9 and 10. These pathways may be easily identified in user interaction 
with MPS by requesting all pathways which lack this enzyme and which produce 
no by-product metabolites. On the other hand, suppose that a cell does not have 
the ability to use the ED pathway, but is able to use both the EMP and the pentose 
phosphate pathway (wild type E. coli does not use the ED pathway, but uses both 
EMP and pentose phosphate pathways to catabolize glucose 33). The enzymatic 
activity in the ED pathway (Pathway 7) that is not contained in either the EMP 
pathway (Pathway 9) or the pentose phosphate pathway (Pathway 5) consists of two 
enzymes: phosphogJuconate dehydratase and phospho-2-keto-3-deoxy-gluconate al­
dolase. Therefore, in order to establish the ED pathway in E. coli, the genes for 
these two enzymes must be introduced into the organism.
MPS also identifies the groups of enzymes indicated in Table 1.2. Each group 
has the property that, when one enzyme of the group appears in one of the ten path­
ways, the rest of the enzymes in that group also appear. There are two enzymes, 
glucosephosphate isomerase and triosephosphate isomerase, defining single enzyme 
groups. Both of these enzymes catalyze reversible isomeration reactions and, de­
pending on the direction that the reactions proceed, produce intermediate metabo­
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lites that are consumed by other groups. There are also six multienzyme groups. 
The first enzyme in each group catalyzing a reaction irreversible under physiological 
conditions commits its substrate(s) to all of the reactions of the group. It can be hy­
pothesized, then, that metabolic regulation has been most likely designed to affect 
the enzymatic activity of the first enzyme in each group catalyzing an irreversible 
reaction. This statement is true for amino acid biosynthetic pathways. 34 This 
heuristic approach leads to the identification of five important enzymes: phospha- 
gluconate dehydrogenase, glucose 6-phosphate dehydrogenase, phosphogluconate 
dehydratase, glyceraldehyde phosphate dehydrogenase, and 6-phosphofructokinase 
(according to the information in the data base, none of the enzymes in the sixth 
group catalyzes an irreversible reaction), that should be considered the most im­
portant of the set of twenty-two enzymes involved in the ten catabolic pathways 
found.
Finally, as shown in Table 1.1, the overall reaction for each of the ten path­
ways involves different utilization/production stoichiometry for ATP, NADH and 
NADPH. This information is important, and will be used in the future to further 
classify the pathways with respect to cellular objectives and to deduce information 
about the regulation of glucose catabolism.
1.4 Pathways Involving By-Products
We have examined the pathways that convert glucose 6-phosphate to pyruvate and 
do not produce any carbon-carrying by-products. The remaining pathways gener­
ated by MPS involve the coproduction of pyruvate and some other carbon-carrying 
intermediate metabolite. In order to further illustrate how MPS can be used, two 
of these pathways will be examined next.
Assume that:
1. A given microrganism catabolizes glucose 6-phosphate via the pentose phos­
phate pathway, and
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2. Erythrose 4-phosphate (a precursor for the biosynthesis of L-tyrosine) is a bio- 
product of interest, and we want the catabolic pathway to lead to production 
of erythrose 4-phosphate and pyruvate.
By screening the pathways generated to pyruvate by MPS for those that pro­
duce erythrose 4-phosphate as well, the genetic modifications required to transform 
the wild-type microorganism to one with the desired property are readily identified. 
There is one pathway, using a subset of the enzymatic activity found in the pentose 
phosphate pathway, leading to the concurrent production of pyruvate and erythrose 
4-phosphate. The pathway is shown in Figure 1.6. Compared with the full pentose 
phosphate pathway (Pathway 9 in Figure 1.2), it is easily identified that the differ­
ence is deletion from the pentose phosphate pathway of the enzyme transketolase-2, 
catalyzing the reversible reaction:
xylulose 5-P + erythrose 4-P τ± fructose 6-P + glyceraldehyde 3-P
Therefore, deletion of this enzyme is the genetic modification required for the con­
current production of pyruvate and erythrose 4-phosphate in this hypothetical mi- 
crorganism. The user may readily draw this conclusion by comparison of the two 
pathways, but this result could also be determine directly by using the screening 
capabilities of MPS.
Consider now the case of a microorganism that catabolizes glucose 6-phosphate 
only by the pathway shown in Figure 1.5. The enzymatic activities involved in this 
pathway are presumed to be the only carbon catabolism activities present in this 
hypothetical microorganism. Assume further that the enzyme glucose 6-phosphate 
dehydrogenase, catalyzing the first reaction of this pathway:
glucose 6-phosphate + NADP+ → D-glucono-d-lactone 6-phosphate -(- NADPH
is deleted. Then the pathway is eliminated, and given the remaining enzymatic 
activity in the microrganism, it appears that there is no way of converting glucose 
6-phosphate to pyruvate (with or without by-products), at least none that is obvious
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from Figure 1.1. However, MPS has synthesized a possible pathway for this case. It 
produces sedoheptulose 7-phosphate in addition to pyruvate, and it is schematically 
shown in Figure 1.7. Note the pseudocatalytic role that glyceraldehyde 3-phosphate 
and erythrose 4-phosphate play in order to accommodate the production of xylulose 
5-phosphate. This feature of MPS will be further examined in the following section.
2 PYRUVATE TO L-ALANINE
In order to further illustrate the capabilities of MPS, the conversion of pyruvate to 
L-alanine has also been analyzed. The classical route for the production of L-alanine 
from pyruvate is through a simple transamination reaction: 32
pyruvate + L-glutamate L-alanine + 2-oxoglutarate
Since the starting substance is pyruvate and L-glutamate is also required, in 
order for the above reaction, which is catalyzed by alanine aminotransaminase, to 
be carried out, L-glutamate must first be formed from pyruvate. However, the 
immediate precursor of L-glutamate is 2-oxoglutarate. Therefore, the pyruvate to 
L-glutamate pathways can be decomposed to two parts:
• A pathway converting pyruvate to 2-oxoglutarate, and
• A pathway converting 2-oxoglutarate to L-glutamate.
However, 2-oxoglutarate is produced by the alanine transamination reaction. There­
fore, only the reaction(s) transforming 2-oxoglutarate to L-glutamate are required 
from the pyruvate to L-glutamate pathways.
MPS has been designed in such a way that an expanding pathway cannot utilize 
an enzyme unless all the substrates are present. The products of any given reac­
tion can only be used for the expansion of a pathway only if the reaction itself has 
been already utilized by the pathway. Therefore, MPS, by design, does not “know” 
that a molecule of 2-oxoglutarate is produced by the transamination reaction, and, 
therefore, 2-oxoglutarate cannot provide the required L-glutamate. The strategy of
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using 2-oxoglutarate (or any other substance in an analogous case), can be easily 
incorporated in the existing version of MPS, but it will greatly increase the required 
execution time, since for each search problem several subsearching tasks (for our 
example, generate L-glutamate from 2-oxoglutarate in addition to the main task 
of conversion of pyruvate to L-alanine). The strategy that has been actually em­
ployed by MPS was the following: it produced L-glutamate from pyruvate, and, 
when the transamination reaction took place, MPS observed the regeneration of 2- 
oxoglutarate and eliminated the pathways leading from pyruvate to 2-oxoglutarate. 
The drawback in such a design principle can be illustrated in the following example: 
Assume that a microorganism does not have the enzymatic activity to produce 2- 
oxoglutarate from pyruvate, but has the enzyme L-glutamate dehydrogenase which 
converts 2-oxoglutarate to L-glutamate. Then if MPS was implemented with a data 
base reflecting the enzymes of this hypothetical microorganism, it wouldn’t be able 
to carry out the transamination reaction, and the program would not report that 
L-alanine could be produced by this reaction. This pathway, however, would be 
found if the enzymatic data base employed by MPS was “conservatively” built,
i.e., no relevant enzymatic activities were absent from the data base even if these 
activities were absent from a given microorganism.
MPS synthesis for the conversion of pyruvate to L-alanine produced four path­
ways. The third pathway involves the set of reactions discussed in the previous 
paragraph. This pathway is also shown in Figure 1.8. There is, however, a second 
way to convert 2-oxoglutarate to L-glutamate, involving an intermediate step of 
glutamine production. This second way has been utilized by MPS in order to pro­
duce the fourth pathway reported which is also shown schematically in Figure 1.8, 
where the additional reactions are noted with dotted lines.
Two more pathways were also reported by MPS. These pathways produce hy­
droxypyruvate as a byproduct; the first one is shown in Figure 1.9 and schemati­
cally in Figure 1.10. The second pathway involves the alternative reaction set to 
convert 2-oxoglutarate to L-glutamate. These two pathways incorporate a differ­
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ent transaminase, serine pyruvate aminotransferase, in order to produce alanine. 
Therefore, a cell possessing the enzymes listed in Figure 1.9 is capable of producing 
alanine even in the case that alanine aminotransferase has been inactivated.
At this point, it is also appropriate to comment on another aspect of MPS. MPS 
is not capable of predicting reactions which might be catalyzed by enzymes unknown 
to the program. The pathways synthesized by MPS depend on what enzymes and 
corresponding reactions are stored in the data base. The data base at this time 
does not have the description of the enzymes that convert hydroxypyruvate to 3- 
phospho-glycerate. Therefore, additional pathways that would have converted the 
hydroxypyruvate by-product to 3-phospho-glycerate, hence eliminating the need 
for the pyruvate to 3-phospho-glycerate pathway incorporated in pathways 1 and 
2, have not been reported.
CONCLUSION
MPS is an easily expandable prototype for the synthesis and analysis of metabolic 
pathways. The design principles used lead to the efficient use of the enzyme data 
base. As has been illustrated, by the given examples, MPS has the ability of han­
dling complex reaction pathways. The first example, glucose 6-phosphate to pyru­
vate conversion, illustrated the ability of MPS to synthesize the catabolic pathways 
of glucose that have been already reported in the literature. MPS can be equally 
useful in exploring less examined areas of the metabolic network and in producing 
valuable information about the effects that addition and/or deletion of certain en­
zymatic activities will have on the production of metabolites and bioproducts of 
interest.
MPS relies totally on the information stored in the data bases. By storing 
more enzymatic activities, further insight into the structure and functionality of 
the metabolic network can be obtained by the user. The data bases can be also 
expanded in another way. With each enzyme can be associated a description of the
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organisms in which the enzyme activity is present. That will allow the immediate 
identification of pathways consistent with the genotype of a single organism, and 
therefore we can identify organisms capable of producing a bioproduct of interest. 
Furthermore, for each enzyme we can also include information about the gene that 
codes for the enzyme. This information can include the set of organisms in which an 
active gene product can be expressed, enabling identification of the candidate-genes 
that should be introduced into a organism through a plasmid, in order to make an 
organism capable of using pathways that the wild-type genotype lacks.
The information stored in the substance data bases can also be expanded. By 
including for each substance the set of organisms that have the ability to uptake 
this substance from the environment or secrete this substance to the environment, 
then MPS could identify overall fermentation equations and appropriate substrates 
that should be used in order to direct metabolism to the production of a desired 
biochemical.
Finally, the results provided by MPS can be used to classify pathways with re­
spect to cellular objectives and for the identification of possible control points of 
the metabolic network. Preliminary results in this direction have been presented 
recently, 35 and more extensive applications of MPS for this purpose will be pre­
sented in future publications.
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1 2 3 4 5 6 7 8 9 10
GLUCOSE 6-P -0.6 -0.5 -0.6 -0.6 -1.0 -1.0 -0.5 -0.5 -0.5 -0.5
CO2 0.6 0.0 0.6 0.6 3.0 3.0 0.0 0.0 0.0 0.0
ATP 0.8 0.5 -0.4 1.6 2.0 0.0 1.0 0.0 1.5 -0.5
NADH 0.6 0.5 0.0 1.0 1.0 0.0 0.5 0.0 1.0 0.0
NADPH 1.2 0.0 1.2 1.2 6.0 6.0 0.5 0.5 0.0 0.0
Ferrocytochrome C 0.8 1.0 2.0 0.0 0.0 2.0 0.0 1.0 0.0 2.0
TABLE 1.1. The overall stoichiometry of the ten pathways converting glucose 
6-phosphate to pyruvate with no carbon-carrying side products (except CO2) nor­
malized on the basis of production of one mole of pyruvate. The stoichiometric 
coefficients for ADP, NAD+, NADP+ and Ferricytochrome C have the same values 





1 2 3 4 5 6 7 8 9 10
P-GLUCONATE DEHYDROGENASE √ √√√√
RIBOSE-P ISOMERASE √ √√√√








GLYCERALDEHYDE-P DEHYDROGENASE √√ √√ √ √
P-GLYCERATE KINASE √√ √√ √ √
P-GLYCEROMUTASE √√ √√ √ √
ENOLASE √√ √√ √ √
PYRUVATE KINASE √√ √√ √ √
GLUCOSE-P ISOMERASE √ √√ √√
6-P-FRUCTOKINASE √√√√ √√
FRUCTOSE-BI-P ALDOLASE √√√√ √√
TRIOSE-P ISOMERASE √√ √ √√√
METHYLGLYOXAL SYNTHASE √√√ √ √ √
GLYOXYLASE I, II √√√ √ √ √
LACTATE DEHYDROGENASE (CYTOCHROME) √√√ √ √ √
TABLE 1.2. Enzyme participation in the ten pathways converting glucose 6 
phosphate to pyruvate with no carbon-carrying side products (except CO2).
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FIGURE 1.1: The part of the metabolic chart related to glucose 6-phosphate catabolism.
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PATHWAY 4





8. PHOSPHOGLUCONATE DEHYDROÔENASE (v = 0.6)
4. RIBOSEPHOSPHATE ISOMERASE (v = 0.2)
5. RIBULOSEPHOSPHATE 3-EPIMERASE (v = 0.4)
6. TRANSKETOLASE-1 (v = -0.2)
7. TRANSALDOLASE (v = 0.2)
8. TRANSKETOLASE-2 (v = 0.2)
β. 6-PHOSPHOFRUCTOKINASE (v = 0.4)
10. FRUCTOSE-BIPHOSPHATE ALDOLASE (v = 0.4)
11. TR1OSEPHOSPHATE ISOMERASE (v = 0.4)
12. GLYCERALDEHYDE-PHOSPHATE DEHYDROGENASE (v = 1.0)
13. PHOSPHOGLYCERATE KINASE (v = 1.0)
14. PHOSPHOGLYCEROMUTASE (v = 1.0)
15. ENOLASE (v = 1.0)
16. PYRUVATE KINASE (v = 1.0)
The overall reaction is:
0.6 D-GLUCOSE 6-PHOSPHATE 1.2 NADPH
1.2 NADP+ 0.4 H2O





The participating enzymes are:
1. GLUCOSEPHOSPHATE ISOMERASE (v = 0.5)
2. 6-PHOSPHOFRUCTOKINASE (v = 0.5)
8. FRUCTOSE-BIPHOSPHATE ALDOLASE (v = 0.5)
4. TR1OSEPHOSPHATE ISOMERASE (v = 0.5)
5. GLYCERALDEHYDE-PHOSPHATE DEHYDROGENASE (v = 1.0)
6. PHOSPHOGLYCERATE KINASE (v = 1.0)
7. PHOSPHOGLYCEROMUTASE (v = 1.0)
8. ENOLASE (v = 1.0)
δ. PYRUVATE KINASE (v = 1.0)









FIGURE 1.2: Two of the pathways produced by MPS for the conversion of glucose 6 
phosphate to pyruvate. Pathway 4 has been identified as the pentose phosphate 































[1,3-diP-g∣ycerate]------► [3-P-g∣ycerate]---------► [2-P-g!ycerate]-------------- ► [PEP]
I
[pyruvate]
FIGURE 1.5: Schematic representation of a variation of the pentose phosphate pathway
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The participating enzymes are:
1. GLUCOSE-6-PHOSPHATE DEHYDROGENASE (v = 1.0)
2. GLUCONOLACTONASE (v = 1.0)
3. PHOSPHOGLUCONATE DEHYDROGENASE (v = 1.0)
4. RIBOSEPHOSPHATE ISOMERASE (v = 0.5)
5. RIBULOSEPHOSPHATE 3-EPΣMERASE (v = 0.5)
6. TRANSKETOLASE-1 (v = -0.5)
7. TRANSALDOLASE ∙ (v = 0.5)
8. 6-PHOSPHOFRUCTOKINASE (v = 0.5)
9. FRUCTOSE-BIPHOSPHATE ALDOLASE (v = 0.5)
10. TRIOSEPHOSPHATE ISOMERASE (v = 0.5)
11. GLYCERALDEHYDE-PHOSPHATE DEHYDROGENASE (v = 1.0)
12. PHOSPHOGLYCERATE KINASE (v = 1.0)
13. PHOSPHOGLYCEROMUTASE (v = 1.0)
14. ENOLASE (v = 1.0)
15. PYRUVATE KINASE (v = 1.0)












FIGURE 1.6: A variation of the pentose phosphate pathway that leads to the concurrent 






























The participating enzymes are:1. LACTATE DEHYDROGENASE (CYTOCHROME)2. GLYOXYLASE I, ∏3. METHYLGLYOXAL SYNTHASE4. TRIOSEPHOSPHATE ISOMERASE5. GLYCERALDEHYDE-PHOSPHATE DEHYPROGENASE6. PHOSPHOGLYCERATE KINASE7. PHOSPHOGLYCERATE DEHYDROGENASE8. L-GLUTAMATE DEHYDROGENASE (NADP÷)9. PHOSPHOSERINE TRANSAMINASE10. PHOSPHOSERINE PHOSPHATASE11. SERINE-PYRUVATE AMINOTRANSFERASE
(v = -1.0) (v = -1.0) (v = -1.0) (v = 1.0) (v = 1.0) (v = 1.0)(v = 1.0)(v = -1.0) (v = 1.0) (v = 1.0) (v = 1.0)The overall reaction is:2.0 PYRUVATE2.0 FERROCYTOCHROME CORTHOPHOSPHATE 2.0 NAD+ADPNH3
NADPH
2.0 FERRICYTOCHROME C H2O2.0 NADH ATP NADP+3-HYDROXYPYRUVATE
L-ALANINE
FIGURE 1.9: One of the four pathways that MPS synthesized for the conversion of
pyruvate to L-alanine.
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FIGURE 1.10: The schematic representation of the pathway show in Figure 9.
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CHAPTER 2




Recombinant DNA technology is now in transition from laboratory scale investiga­
tion to production scale application. Several proteins such as insulin and interferon are 
now being produced on significant scale.1 The stability of the plasmid or other recom­
binant DNA vector may be one of the most important factors in large-scale production 
using genetically engineered cells.
A number of previous investigators have proposed and analyzed mathematical 
models describing genetic instability in growing cultures. General models for genetic 
stability and its effects during continuous cultivation of microorganisms have been 
developed in detail by Moser.2 More recently, a number of investigators have calculated 
the effect on overall cell population properties of plasmid loss at cell division and of 
differences in growth rates of plasmid-free and plasmid-containing cells.3-8
Also important for design and analysis of reactors for recombinant organisms are 
descriptions of cloned-gene product formation. Previous analyses by Ollis and Chang8 
considered product formation in recombinant cultures using the empirical Leudeking- 
Piret equation for product formation kinetics. Seo and Bailey presented overall cloned- 
gene product formation calculations based on a segregated model and empirical single­
cell product synthesis kinetics.9 Recently, models for product synthesis in recombinant 
systems have been formulated based upon the molecular mechanisms involved.10 In this 
work, the previously developed genetically structured model for product formation in 
recombinant cells is extended to describe the kinetics of cell growth and product forma­
tion in fermentation of unstable recombinant cells in batch and continuous reactors.
One purpose of this work is to develop mathematical expressions for calculating 
product formation which are formulated at the single-cell level and elaborated to allow 
calculations at the reactor level. Second, the models will be applied to determine reactor 
performance and to examine the sensitivity of reactor performance to certain process and
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host-vector design parameters. The simulation results indicate that there may be an 
optimum copy number or an optimum transcription efficiency of the cloned gene for 
maximizing reactor productivity. Also, the apparent stability of the genetically 
engineered cell is determined not only by the intrinsic stability parameters associated 
with plasmid segregation and mutation but also by the product synthesis activity of the 
cell and by reactor operating conditions such as dilution rate in a continuous fermentor.
BACKGROUND
Stability of Recombinant DNA
Schematic representation of a recombinant DNA expression plasmid is shown in Fig. 
2.1 A. The essential components of recombinant DNA are a (foreign) gene fragment of 
interest (G in Fig. 2.1 A) and a cloning vector which serves to propagate that DNA seg­
ment in the host cell. Plasmids, phages, or their derivatives are widely used for cloning 
vectors. For stable maintenance of recombinant DNA in proliferating host cell popula­
tions, the vector should carry a minimal replicon (R in Fig. 2.1 A), that is, the genes and 
genetic sites required for replication and possibly also for segregation. In addition, selec­
tion markers (M in Fig. 2.1 A) providing antibiotic resistance or complementation of host 
cell mutations are usually introduced into a cloning vector because the replicon itself 
often has no detectable phenotypic effect on the host cells.
During propagation of recombinant DNA in microbial cells, however, a loss of 
desired phenotype is often observed. This phenomenon can occur through two processes 
called "segregational instability" and "structural instability" (Fig. 2. IB).11 Segregation 
instability refers to the loss of the entire recombinant DNA from the cell due to irregular 
segregation of the cloning vector at cell division.12,13 On the other hand, a recombinant 
DNA is frequently subjected to various types of structural rearrangements such as dele­
tion, insertion, and duplication, causing loss of expression of an active product of one or 
more genes of the recombinant DNA.14-18
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Growth of a recombinant organism in selective medium aids in maintaining a popula­
tion of cells containing the vector which still possesses the selection marker phenotype. 
Thus, application of selection pressure can be used to reduce the damage of segregational 
instability in a process for manufacturing a cloned-gene product. Since, however, the 
gene product of the selection marker is usually not the product of commercial interest 
and since there is typically no method for direct selection of the desired product pheno­
type, selection pressure does not eliminate or control structural instability. The cell 
population may maintain the recombinant DNA but lose the ability to express a desired 
gene product in active form.
Effect of Cloned Gene Expression on Host Cell Growth
Since a recombinant DNA is composed of a cloning vector and a cloned DNA seg­
ment and since these two elements are not necessarily propagated together in the hetero­
geneous populations found in unstable recombinant cultures, the effect of the cloning 
vector and the effect of cloned gene expression on the host cell growth rate are con­
sidered here separately. In the models examined in this work, it is assumed also that 
functional dependence of specific growth rate on limiting nutrient concentration s, cion- 
ing vector concentration G, and cloned gene product concentration p is separable. Thus
μ = μ0f(s)g(G)h(p) . (2.1)
It has been reported that the presence of certain plasmids has a deleterious effect on 
host cell growth.19-21 Since common precursors, catalytic assemblies, and energy sup­
plies provided by the host cell are required for biosynthetic processes of both plasmid- 
encoded genes and chromosomal genes, competition between the cellular activities 
directed by the plasmid and the bacterial chromosome may occur. Supporting this 
hypothesis, Nordstrom et al.22 and Seo and Bailey23 have reported that the growth rates 
of different strains containing a series of plasmid copy mutants were reduced
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significantly in cases where the plasmid copy number was relatively large. Previous 
simulation results based on an intracellular model including competition for RNA polym­
erase predict that transcription efficiency of both plasmid and chromosomal genes is 
greatly reduced as the plasmid copy number increases.10 Based on the previous model 
simulation and the experimental data mentioned, the following relationship between the 
cellular content of plasmid gene copies and host-cell growth rate is a reasonable func­




The effect of plasmid copy number on the host-cell metabolic activity depends largely on 
the nature of plasmid replicon, the particular genes and control loci encoded in the 
plasmid, and the genetic background of the host cell. As a consequence, the two parame­
ters appearing in Eq. (2.2), Gτnax and m, can be affected by these genetic factors as well 
as by environmental conditions.
Although many genes have been successfully cloned and expressed in recombinant 
microorganisms, accumulated data for several of these host-vector expression systems 
shows that expression of the amplified, cloned gene inhibits cell growth and survival. 
Such inhibitory effects appear even more pronounced when the expression product of the 
cloned gene is a highly hydrophobic protein such as a membrane protein, a hormone, or 
an interferon.24-26
Practical motivations for genetic engineering include production of valuable peptides 
or proteins and desirable alteration or enhancement of host cell metabolic activities or 
functions. In both cases, it is important to consider the locus of accumulation of the pro­
duct. Synthesis of cloned gene products in the most widely used host, E. coli, usually 
results in intracellular accumulation of the cloned gene product. Limited successes in 
secretion of cloned gene products from E. coli into the medium have been reported.27,28
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In an ideal expression-secretion system, almost all of the cloned gene product will be 
found in the cell environment. Similarly, it is expected that most product metabolites 
will be found outside the cell in useful strains with metabolic enhancements provided by 
genetic engineering. However, even in this instance and for secreted proteins (and 
indeed for many other microbiological processes), the product concentration inside the 
cell will likely exceed the product concentration in the medium.
Two different models for product inhibition will be considered. In the first, the inhi­













Model II is of the form applied previously to several fermentations,29 but Model I seems 
intuitively more reasonable in many cases and certainly is the required form when all of 
the product accumulates intracellularly. One objective of this modeling study, then, is to 
explore the sensitivity of calculated bioreactor performance to different types of product 
inhibition.
Using Eqs. (2.2) and (2.3) or (2.4) to calculate the influences of plasmid and cloned- 
gene product content on cell growth implies (see Eq. (2.1)) that cells without plasmids 
and product grow more rapidly than plasmid-containing and productive cells. Thus, this 
model corresponds to use of non-selective medium. Extension of this overall produc­
tivity model to selective medium requires careful consideration of growth rates at small 
plasmid content and growth of plasmid-free cells. Experiments and model analyses of
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these questions have only recently begun.30
Product Formation
The empirical formula suggested by Leudeking and Piret31 has been widely used in 
previous descriptions of product formation kinetics. In the case of a recombinant DNA 
system, however, it is now possible to describe product formation based on the 
corresponding molecular mechanisms. Mathematical expressions for the synthesis of 
messenger RNA and protein via transcription and translation processes have been 
presented previously (e.g., Ref. 10). Assuming that the decay of cloned gene mRNA and 
of the corresponding protein follow first-order kinetics, the intracellular concentration of 
cloned-gene message (m) and protein (p) can be described by the following material bal­
ances:
= k^ηG - kdm - μm (2.5)
= kq0ξfh - kep - μp (2.6)
where k£, k°, kd, and ke are the overall transcription rate constant, overall translation rate 
constant, decay constant of mRNA, and decay constant of protein, respectively. The 
symbols η, ξ, and μ denote the transcription efficiency, translation efficiency, and 
specific growth rate, respectively. As discussed in a previous paper, k£ and k£ are func­
tions of growth rate10; kd and ke are presumed relatively independent of growth rate.
Since (kd + μ) ≈*>(ke + μ), the quasi steady-state approximation32 can be applied to m;
i.e., m may be approximated by the equation implied by setting dm/dt = 0:
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(2.7)
Substituting Eq. (2.7) in Eq. (2.6) gives
& = f(μftG-kep-μp , (2.8)
where
(2.9.1)
and the "gene expression parameter" γis defined by
γ = ηξ . (2.9.2)
Notice that γ depends on the cloned-gene promoter and ribosome binding site "strengths" 
as indicated in the parameters η and ξ, respectively. This quantity can be altered by 
changing the plasmid construction or, if suitable controls are incorporated in the plasmid, 
by changing medium composition or temperature.
Dependencies of the parameters k£ and k° on specific growth rate for (plasmid-free) 
E. coli have been estimated previously based on literature data.10 Unfortunately, little 
data are presently available for estimating these kinetic parameters in the presence of 
plasmids. Presumably both depend on plasmid content (see, for example, Ref. 33). In 
the absence of more information, the correlations previously described are used here for 
plasmid-containing cells.
In order to explore relationships between these kinetics and other overall forms used 
in previous studies, an approximate form of product synthesis kinetics will also be con­
sidered. In this model, the function f(μ), which is a complicated nonlinear function of 
specific growth rate μ, will be approximated by a linear function
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f(μ)≡k(μ + b) (2.10)
where k and b are constants.
KINETIC MODEL
The kinetic model developed here is based on the following assumptions:
1. The number of plasmids per R+ cell is constant during cultivation of recombinant 
cells (actually G = f(μ)10,23, and an appropriate relationship can be determined from 
a plasmid replication model10,34).
2. The mutation frequency of the cloned gene and the frequency of plasmid loss due to 
irregular segregation are assumed to be constant irrespective of host cell growth rate 
and culture conditions.
3. The cell population is presumed to consist of three different genetic classes accord­
ing to the presence or absence of plasmids and according to expression of active 
cloned-gene product (see Fig. 2. IB). Another possible combination [G+R-] is not 
considered here based on the experimental observations of Imanaka et al.r7
Batch Culture
(a) Cell Growth
Let θ and φ denote the ratio of the mutation rate of structural genes to the host cell 
growth rate and the ratio of segregational plasmid loss rate to the growth rate of the host 
cell, respectively. Then the following equations for densities of strains with genotypes 1 
through 3 (G+R+, G+R^, and G^R~, respectively) can be derived from the scheme of 
genetic changes outlined in Fig. 2.IB:
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= μ1x1(l-θ-φ) Δ μ1χ1 (2.11)




— = μ3x3 + μ1x1φ + μ2x2φ (2.13)
In Eq. (2.11), μ1 denotes the apparent (or overall) specific growth rate of the product- 
synthesizing subpopulation. Growth in a well-mixed, isothermal batch reactor is 
assumed in writing these cell balances.
The specific growth rate of each species, μj, will be written:
and






Pmax. Ks + s l b J
= μ0f(s)g(G)h(p)












for Model I while μ1 = μ0f(s)g(G)h(p) for Model II (cf. Eqs. (2.3),(2.4)). Here, for the 
sake of simplicity, the Monod constants, Ksj, of each species (j = 1, 2, and 3) for limiting 
substrate, s, are assumed to be identical. The maximum specific growth rate of each 
species has been written to include inhibition by the vector or the cloned gene product 
depending on the presence of each of these factors in each of the three strains. This is a 
key feature of this model.
(b) Substrate Consumption
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Presuming constant stoichiometric ratios (yield factors), the rate of substrate con­
sumption can be obtained from a mass balance equation of the form
ds _ y 1 dxj 1 dp
dt Ysj dt Yp dt (2.17)
For convenience, the second term is considered to be negligible in this paper. Assuming 
Ysj is not significantly different for each cell type, Eq. (2.17) becomes
ds_ = __1_ dχ1 dx2 dx3 
dt ^ Ys dt + dt + dt (2.18)
(c) Product Formation Kinetics
As shown in the previous section, product formation, which occurs only in Species 1, 
is calculated using either Eqs. (2.8) and (2.9) or the approximate model corresponding to 
Eq. (2.10). In either case, the overall specific growth rate of species 1, μ1, is used to cal­
culate the growth-rate dependence of product synthesis.
Since p is the intracellular product concentration, it is important to convert this value 
to product concentration in the culture volume in order to assess reactor productivity. 
The required relationship is
p = px1∕pb (2.19)
where pb is the density of the bacterial cell (cell mass/unit volume cell). Differentiating 
this gives






assuming pb is independent of time. This is a reasonable assumption for plasmid-free 
bacteria35; little data are presently available on the density of recombinant strains and its
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variability.
It is interesting to explore the connection between these product formation kinetics 
based on mechanism and those of traditional Leudeking-Piret form. Substituting Eqs. 
(2.8) and (2.10) into Eq. (2.20) gives




^^dt^^ + bx1 -kep. (2.21)
Eq. (2.21) is nearly identical to the empirical equation of Leudeking and Piret.31 Consid­
ering only the kinetics of protein synthesis and accordingly neglecting the protein decay 
term, Eq. (2.21) becomes
⅛ = ≈⅛ + βx1 (2.22)
dt 1 , . dt
∣synthesιs
where
α = kηξG∕pb , β = a ∙ b . (2.23)
Here, the structured model provides an interpretation for the (typically empirical) 
Leudeking-Piret parameters.
Continuous Culture
Material balances for cell concentration,, substrate concentration, and product forma­
tion for continuous cultures with sterile feed may be developed in a manner analogous to 
that described above for batch cultures, with the results
dx1
~dt^ = -Dx1 + μ1xj(l - θ - φ) (2.24)
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dx2
----- = -Dx2 + μ2×2(l ~Φ) + Uιxιθdt
(2.25)
dx3
= Dx3 + μ3x3 + μ1x1φ + μ2x2Φ 
dt
(2.26)
⅛ = D(so - s) - (μ1x1 + μ2x2 + μ3*3)
dt Ys
(2.27)
dp __ f(^i) tA 1
= -Dp + ηξGx1 kep
dt pb
(2.28)
where D and s0 represent the dilution rate and inlet substrate concentration, respectively.
SIMULATION RESULTS
Model Parameters
The parameters used for model simulations are listed in Table 2.1. The maximum
specific growth rate, μo, the Monod constant, Ks, and the yield coefficient, Ys, were taken 
from values for E. coli cells growing in glucose medium in the absence of plasmids or 
cloned gene expression.36 Although experimental data are limited, it has been reported 
that the Ks and Ys values of plasmid-containing cells are not significantly different from 
those of plasmid-free cells while μ0 is significantly affected due to the presence of 
plasmids.20,21’23,37 Accordingly, as noted earlier, it is assumed here that the Ks and Ys 
values for each cell type are identical.
The exponent m was set equal to 0.5 based on the experimental data of Nordstrom et 
al. In the absence of available information on the exponent for product inhibition, n 
was assumed to be either zero (no product inhibition) or 1. Although the values of 
Gmax and Pmax (Pmaχ) maY highly dependent upon the nature of the cloning vector and 
of the cloned gene product as well as the genetic background of the host cell, the parame­
ters listed in Table 2.1 are reasonable based on maximal product levels reported to date 
and were used for these simulations. Since the purpose of these simulations is to
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investigate qualitative trends influencing the productivity of recombinant microorgan­
isms, several parameters such as β and ke, which do not significantly affect the conclu­
sions of model simulation, were assumed to be negligible.
Evaluation of f(μ) in Eq. (2.9.1) using k^,(μ) and k°(μ) from Lee and Bailey10 gives
g(g) Δ = 4.5×101°μ4
kd + μ (78μ2+233)(145μ+82.5)(27.<⅛μ)
(hr-1> (2.29)
where μ has units of hr 1. Two different linear approximations to f(μ), with form given 
by Eq. (2.10), are considered. The first, chosen to coincide with g at μ = o and μ = μ0, is
h(μ) = 10,900μ (hr-1), (2.30)
and the second, chosen somewhat arbitrarily to represent an intermediate case better 
approximating growth rates for plasmid-containing cells, intersects g at a μ value 
corresponding to 50 plasmids and no product, giving
∕(μ) = 7300μ(hr^1). (2.31)
These three different protein synthesis rate functions are plotted versus specific growth 
rate μ in Fig. 2.2.
The plasmid concentration G(g∕l) is calculated from the number of plasmids per cell 
Np using the relationship
G = 0.0001186 Np (2.32)
which is based upon representative plasmid size and cell volume for E. coli.10
Batch Cultures
In Fig. 2.3 computer simulation results for batch cultivation of recombinant cells are 
shown using the model described above with f(μ) given by the complete Eq. (2.9) and
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with no product inhibition (n=0). The changes in x1, x3, p, and s with time during fer­
mentation were obtained from the numerical solutions of Eqs. (2.11)-(2.13),(2.18), and 
(2.21). The initial conditions used in these calculations are summarized below:
s(0) = 30 g/1
x1(0) = 0.001 g/1 (2.33)
x2(0) = x3(0)=p(0)=0 .
In these calculations, the values of θ and φ were assumed to be 0 and 0.01, respectively, 
which corresponds to the case of pure segregational instability. The calculations were 
conducted for several different values of plasmid content Np to show the influence of this 
key parameter.
These simulations show a number of interesting features. As plasmid content 
increases, the time required to reach stationary phase (substrate exhaustion) increases, the 
final concentration x1 of plasmid-containing, productive cells decreases, and there is a 
corresponding increase in the final concentration of plasmid-free cells (x3). However, 
batch fermentations at smaller (Np= 10) and larger (Np= 100) plasmid content give 
significantly less final cloned-gene product than batch cultivation of a strain with inter­
mediate plasmid content (Np = 60). Thus, the calculations indicate the existence of an 
optimum plasmid content for maximizing process productivity.
Recently Aiba et al.3% examined experimentally the relationship between the produc­
tion of tryptophan and the the copy number of plasmids using recombinant DNAs with 
the trp operon cloned into four different plasmid vectors RP4, pSC101, RSF1010, and 
pBR322. They found that accumulation of tryptophan in the culture medium decreased 
when the copy number exceeded a certain level. According to their report,38 the max­
imum tryptophan concentration in the culture medium was 1.7, 3.1, and 2.6 g/1 for RP4,
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pSC101, and RSF1O1O, respectively. The copy numbers corresponding to these plasmids 
are approximately 2, 5, and 15, respectively.38,39 The time trajectories of cell growth, 
substrate consumption, and product formation shown in Fig. 2.3 resemble qualitatively 
the experimental data of Aiba et al. for shake flask culture of the recombinant trp system 
cloned into RP4, pSC101, and RSF1010, respectively.38
More details on the influence of plasmid content on final product concentration are 
shown in Fig. 2.4 which summarizes the results of many batch fermentation simulations. 
Circles show calculated product levels after substrate exhaustion based on the model 
parameters used above (θ = 0.0, φ = 0.01; pure segregational instability), and on f(μ) 
given by Eq. (2.29). To evaluate the influence of the approximation introduced by using 
a linearized form of f(μ) (Leudeking-Piret kinetics), batch reactor simulations were also 
completed for f(μ) given by Eq. (2.30) (diamonds in Fig. 2.4) and by Eq. (2.31) (squares 
in Fig. 2.4). Clearly, all three functional forms for the dependence of protein synthesis 
rate on specific growth rate give qualitatively similar results: maximum product accumu­
lation at intermediate plasmid content. The linearized model in Eq. (2.31) reasonably 
well approximates results obtained using the full model of Eq. (2.29).







xτ(t) = x1(t) + x2(t) + x3(t) (2.35)
versus the plasmid content in the batch fermentation. The fraction of productive cells 
after substrate exhaustion declines monotonically as plasmid content increases. Because 
no product inhibition was considered in this particular set of calculations, this relation­
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ship is independent of the choice of f(μ).
The effects of the type of instability and of product inhibition based on intracellular 
concentration (Eq. 2.3) or on total broth concentration (Eq. 2.4) are summarized in the 
simulation results plotted in Fig. 2.5. Again, values shown correspond to the end of the 
batch after substrate exhaustion. All cases considered show an optimum in final product 
concentration with respect to plasmid content. However, the maxima are much sharper 
for segregational instability (θ = 0) than for structural instability (φ = 0). Final product 
levels are higher at every plasmid content considered for structural instability than for 
segregational instability independent of the mode of product inhibition.
The qualitative trends for productive cell fraction ψ vary greatly depending on the 
type of instability. For segregational instability, ψ approaches zero as plasmid content 
increases, while the productive fraction dips and then increases for larger plasmid content 
for pure structural instability. This is reasonable since structural genetic instability gives 
plasmid-containing but not productive cells which do not differ greatly in growth rate 
from productive cells at high plasmid content, whereas complete plasmid loss (segrega­
tional instability) gives cells with much greater specific growth rate.
Plasmid construction can influence the gene expression parameter γ (Eq. 2.9.2). If 
product inhibition is not important, it is obvious that γ should be made as large as possi­
ble to maximize product synthesis. However, with product inhibition, simulations with 
the present model indicate an optimum value of γ for the case of intracellular product 
inhibition (Fig. 2.6). Also, these calculations show that the fraction of productive cells is 
influenced by the cloned-gene expression efficiency as characterized here by γ.
Continuous Culture
Calculations for continuous culture of a host-vector system exhibiting pure segrega­
tional instability (φ = 0.01, θ = 0) are shown in Fig. 2.7. Because of genetic instability, 
the behavior of the continuous flow fermentor is intrinsically unsteady. The calculation
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results illustrated in Fig. 2.7 were obtained from numerical solution of the unsteady 
material balances for continuous culture described earlier. The simulations shown here 
are for product inhibition based on intracellular product concentration. Initial conditions 
for the transient continuous reactor, listed below, were determined by simulating batch 
growth from the inoculum given in Eq. 2.34 because this is the usual start-up procedure 
for continuous bioreactors.
s(0) = 29.6 g/1
p(0) = 0.011 g/1 (2.36)
x1(0) = 0.271 g/1
x3(0) = 0.029 g/1 .
These calculations display a number of interesting features. At some dilution rates, 
the total cell concentration drops and then increases. These results are qualitatively con­
sistent with the experimental observations of Aiba and Koizumi40 for continuous culture 
of Bacillus stearothermophilus CU21(pLPll) at 55° C.
The model simulations indicate that the fraction of productive cells, ψ, decreases as 
the dilution rate decreases. Similar behavior is evident in the experimental data of 
Wouters et al.41 They investigated the loss of drug resistance in E. coli cells harboring 
pBR322 in a chemostat under phosphate-limited conditions. Their experimental data 
show that the fraction of drug-resistant cells is lower at lower dilution rate. However, the 
present model does not predict the lags in responses of unstable recombinant cultures 
which have been observed experimentally.41,42 Interestingly, the model without product 
inhibition gives decreasing ψ with increasing dilution rate.
-54-
DISCUSSION
The model for product formation employed here has been derived from a structured 
model which provides a relationship between product formation kinetics and fundamen­
tal biological parameters such as cellular vector content, transcription efficiency, and 
translation efficiency. It is interesting that a linear approximation to the final expression 
resulting from this derivation is identical to the empirical Leudeking-Piret equation for 
product synthesis rate originally formulated for citric acid production. The connection 
may be more than coincidental. If production of a metabolite is limited by certain key 
enzymes and if production of a metabolite is proportional to the amount of key enzymes 
in the cell, the derivation given here provides a possible explanation for the Leudeking- 
Piret form of kinetics, even for metabolites.
The model simulation results indicate an optimum value for intracellular vector con­
centration G and for the product of cloned gene transcription efficiency, η, and transla­
tion efficiency, ξ. These host-vector parameters can be manipulated by both genetic 
engineering and by bioreactor control. For example, plasmid content can be changed by 
modifying the replicon, and gene expression efficiency can be modified by altering the 
promoter, ribosome binding site, and their positions relative to the structural gene. Con­
centrations of replication and expression repressors or activators can be adjusted by 
medium composition or temperature for suitably constructed recombinant strains.
There are several experimental reports which also indicate the existence of an 
optimum plasmid copy number or cloned gene expression activity.38,43-45 One example 
was mentioned earlier. Another is the study of Feinstein et al. who determined the β1- 
inteferon activity in a recombinant E. coli system.43 In the expression plasmid used in 
their studies, the recA promoter-operator was employed for regulation of transcription of 
the interferon gene. The recA promoter-operator activity is induced by nalidixic acid. 
As shown in Fig. 2.8, it was found that an optimum inducer concentration, corresponding
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to an optimum η value, exists. This finding is qualitatively identical to that obtained 
from the present model for the case of intracellular product inhibition. Comparison of 
the present simulation results with other reports44,45 also indicate that the general trends 
obtained from this model showing the existence of an optimal transcription efficiency are 
consistent with currently available experimental information.
In contrast to several previous models concerned with genetic instability and recom­
binant systems, the present model indicates that the fraction of product-synthesizing cells 
is a function of many parameters. This fraction is influenced by genetic parameters 
which determine the intrinsic vector and cloned gene stabilities (φ and θ), the gene 
expression activity γ, the intracellular cloned-gene product concentration p, the nature of 
the cloning vector, the cloned gene and its product, and the host cell. The latter proper­
ties will influence parameters such as Gmax, pmax, and maximum specific growth rate μ0. 
Also, environmental and process operating conditions such as dilution rate and substrate 
concentration influence the fraction of productive cells in the culture.
Product inhibition as described in this model has two different physical inteιpreta- 
tions. The first is actual interference of product molecules or their aggregates with reac­
tions and morphological developments associated with cell growth. Alternately, the total 
amount of product accumulated may be viewed as an integral measure of the cellular 
biosynthetic activity which has been diverted by plasmid product gene expression away 
from synthesis of host cell proteins. Such diversion is expected to reduce host cell growth 
rate.
The success of the present model in simulating trends in fermentations of recom­
binant organisms is quite encouraging and suggests that this framework may prove valu­
able for optimizing production processes for protein manufacture using recombinant sys­
tems at both the genetic and environment/process levels. There is a clear need for greater 
experimental studies of the interrelationships assumed here and calculated as a result of
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this model. Another contribution of this type of simulation study is identification of cer­
tain effects and trends which are sufficiently amenable to measurement and/or are of 
sufficient practical interest to motivate the required experiments. With refined model 
parameters for a particular system, detailed optimization calculations follow directly 
from the present modeling framework.
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A. TYPICAL EXPRESSION PLASMID







FIGURE 2.1: Schematic diagram of basic functional elements in an expression plasmid 
(A) and diagram of genetic transitions in a recombinant population with structural 


























FIGURE 2.2: Alternate forms of the protein synthesis rate function f [Eq. (9.1)] consid­






FIGURE 2.3: Simulated batch bioreactor trajectories for pure segregational instability 









FIGURE 2.4: Calculated productive cell fraction ψ and product concentration after sub­
strate exhaustion in a batch bioreactor as a function of cell plasmid content (pure 
segregational instability; θ=0, φ=0.01, without product inhibition; n=0. Calcula­
tions for f(μ) given by Eq. 2.30 (∙), Eq. 2.31 (0), and Eq. 2.29 (o)).
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cases.
FIGURE 2.5: Dependence of final product content and productive cell fraction after
substrate exhaustion in a batch bioreactor for different instability and product in­
hibition models. Solid symbols correspond to inhibition based on intracellular 
product concentration (Model I), and open symbols correspond to Model ∏ which 
employs overall broth product concentration to evaluate product inhibition. Cir­
cles are for pure structural instability (θ=0.01, φ=0), and squares were calculated 
for pure segregational instability (θ=0, φ=0.01). ∕(μ) given by Eq. 2.29 for all
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FIGURE 2.6: Simulated final productive cell fraction and product concentration versus 
the gene expression parameter, γ, characteristic transcription and translational ef 
ficiency, for product inhibition Model I (∙) and Model ∏ (o). (φ=0.01, θ=0, 
Np=50)
-69-
FIGURE 2.7: Computed time trajectories of total cell concentration and productive cell 
fraction following initiation of continuous-flow bioreactor operation. Dilution 
rates shown: D=0.1,0.2,0.3,0.4,0.5,0.6, and 0.7 hr -1. (φ=0.01, θ=0, product 
inhibition Model I, Eq. 2.29 for∕(μ).)
-70-
FIGURE 2.8: Experimentally measured interferon activity obtained from recombinant 
E.coli fermentation as a function of inducer (nalidixic acid) concentration. In­
ducer concentration is correlated with cloned-gene transcriptional activity (data 
from Ref. 43 of Chapter 2).
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CHAPTER 3
OPTIMAL GENE EXPRESSION AND AMPLIFICA TION 




Maximizing the amount of protein produced from a cloned gene in a recombinant 
organism requires careful consideration of the tradeoffs involved between cloned-gene 
expression and host cell growth and biosynthetic activity. Cloned-gene product synthesis 
is favored by increasing cloned-gene content of the cell (e.g. Refs. 1-4). On the other 
hand, numerous experimental studies of recombinant Escherichia coli and Saccha­
romyces cerevisiae have shown that the presence of plasmids reduces host cell growth 
rate and, concomitantly, overall protein synthesis activity (e.g. Refs. 3, 4). Also, it has 
been observed that induction or derepression of cloned-gene expression accentuates this 
inhibitory effect.! Reduced host-cell growth rates and biosynthetic activity in the pres­
ence of plasmid-directed macromolecular synthesis presumably occurs because of 
competition between plasmid-directed and host cell-directed activity for common pools 
of precursors, chemical energy and electrons, activator species, repressor molecules, 
transport apparatus, and enzymes and other catalytic assemblies.
The use of regulated promoters and plasmid replication controls amenable to envi­
ronmental manipulation offers the opportunity of reconciling the opposing effects of 
cloned-gene content and expression level on process productivity. Several promoters are 
available for E. coli, S. cerevisiae, and other hosts which allow the expression level of the 
cloned gene to be switched from a relatively low to a relatively high level by a change in 
the organism environment.13 Similarly, in a plasmid replicon repressed by a temperature- 
sensitive molecule, such as the ColEl origin of replication for E. coli plasmids with a 
mutant RNA I gene providing temperature-sensitive replication repressor activity,5 
cellular plasmid content can be altered from around 25 to 700 or more copies per cell by 
increasing the medium temperature. Similar temperature-sensitive replicators are known 
forRl plasmids.6
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Such regulated replicons and promoters offer the biochemical engineer the opportu­
nity to optimize process performance through application of optimized environmental 
changes which in turn generate optimal profiles of plasmid content and cloned-gene 
expression levels during the course of the process. In order to explore the influence of 
different operating strategies on recombinant culture product accumulation and also to 
examine the effects of different assumptions concerning host-plasmid interactions, a 
mathematical model previously formulated to describe product formation in unstable 
recombinant cultures has been used.7 Responses of this model to different induction and 
amplification strategies have been calculated for batch and continuous bioreactors. 
Following presentation of these simulation results, the key factors which influence biore­
actor performance and areas requiring further investigation are discussed.
MATHEMATICAL MODEL AND CONTROLS CHARACTERISTICS
The mathematical model of unstable recombinant population growth and product 
synthesis employed in these calculations is presented in detail in Chapter 2. Here, only 
the major qualitative features of the model are summarizes. Although certain details of 
the model are based upon data for E. coli, the qualitative characteristics embodied in the 
model are reasonable for other host organisms. 1 2 *
1. The specific growth rate of cells containing plasmids declines monotonically with 
increasing plasmid content. Cells expressing the cloned gene have decreased 
specific growth rates for increased accumulation of cloned-gene product.
2. The model includes both structural and segregational instability. (Only
segregational instability is considered in these calculations.)
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3. Cloned-gene product protein accumulation is calculated based upon a 
transcription-translation model which includes the growth rate dependence of 
transcription and translation activities.
4. Cell yields based upon substrate utilization are presumed constant and equal for 
all cell types.
It is presumed that the host-vector system has been constructed so that a change in 
culture temperature or concentration of an inducer alters cell plasmid content and cloned- 
gene expression activity. (To avoid cumbersome and repetitive language, gene expression 
regulation will be discussed henceforth only for the case of induction. Analogous consid­
erations apply for derepression.) In the absence of detailed experimental data on the 
kinetics of plasmid amplification and gene expression induction, the particular ramp- 
plateau trajectories shown in Fig. 3.1 are assumed to result after a switch in environmen­
tal conditions causing amplification at time îamp and gene expression after time îexp. 
Thus, expression activity and plasmid content are not assumed to change instantaneously 
to new values.
Although the qualitative features to this simulation model are reasonable and reflect in 
some respects a substantial amount of realistic detail, certain parts of the model, includ­
ing the features just discussed, are approximations based upon limited information. Thus, 
the model employed here is expected to be reasonably for investigating certain qualitative 
trends, but, in the absence of complete and more detailed experimental information for a 
particular host-vector expression system, this model is not expected to afford detailed and 
exact description of a particular production organism. Accordingly, it is appropriate at 
this stage to investigate a reasonable yet limited class of operating strategies. In this 
work, only single switch, bang-bang environmental operating strategies are considered. 
That is, it is presumed in batch reactor operation that, at a particular point in the batch, 
designated tλMP or îexp, the amplification and expression processes, respectively, begin
-75-
and follow the trajectory shown in Fig. 3.1. In continuous bioreactor calculations, it is 
presumed that the overall reactor consists of three vessels (or relatively independent 
mixing domains) in series, that conditions in one domain support growth at the original, 
basal levels of plasmid, that cloned-gene expression are active in one of the following 
vessels, and that both gene amplification and expression are active on the other vessel.
BATCH BIOREACTOR SIMULATION RESULTS
Calculations have been conducted employing the model parameters previously listed.7 
In these calculations, pure segregational instability was considered (θ=0, φ=0.01). 
Product inhibition of host cell growth was calculated based upon the intracellular product 
concentration (Model I, Eq. 2.3). Computational results showing the cloned-gene product 
concentration (grams product per liter of culture) and the fraction of productive plasmid- 
containing cells at the time of substrate exhaustion during the batch are plotted in 
Fig. 3.2. The abscissa is the time of cloned gene expression induction or plasmid amplifi­
cation initiation, designated the switching time. The final maximal gene expression 
activity γf and number of plasmids per cell Np,{⅛aι are here: 1.0 and 50, respectively. In 
each case, it is assumed that the other parameter begins at its "on" or fully induced or 
amplified level. Thus, for calculations exploring the effect of amplification time, gene 
expression is presumed to be 50 from time zero in the case of the calculations of the 
effect of cloned-gene induction.
Clearly, the amount of product synthesized by the recombinant culture is maximized 
by an operating strategy which employs low levels of gene expression during an initial 
growth stage of the batch culture and which switches to high product synthesis activity at 
a suitable point during the batch. The fraction of productive cells in the population 
increases monotonically as the time of switching to high expression and amplification 
conditions is increased. However, this trend plateaus late in the batch. Examining product
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concentration and productive fraction results together indicates that host-plasmid inter- 
action/inhibition phenomena are entirely responsible for the sharp decline in achievable 
product concentration accompanying late switches to expression and amplification. Also, 
if the switch to product synthesis is delayed too long, a certain interval of opportunity for 
product accumulation has been lost and limited time for growth of the culture remains.
With the same model parameters, more extensive simulations have been undertaken 
considering the opportunity to accomplish both gene expression switching and plasmid 
amplification independently at different points during the batch. Both plasmid content 
and cloned-gene expression level are presumed low initially. The final concentration of 
product and the fraction of plasmid-containing, productive cells as a function of these 
two switching times are plotted in Figs. 3.3 and 3.4, respectively. These calculations 
show that the final product concentration is much more sensitive to the switching time 
choices than the final productive fraction. Although perhaps obscured by the perspective 
needed to show the response surface, the greatest product concentration at completion of 
the batch occurs when the switching times for expression and amplification are both 
equal to 10 hrs. Fig. 3.5 illustrates the time trajectories of product concentration and pro­
ductive fraction for these optimal conditions 0αμρ=10 hr., tEχp=10 hr., solid line) relative 
to the uncontrolled case when plasmid content and gene expression level are Np=50 and 
γ=1.0 throughout the batch. Optimal operating conditions for the particular parameters 
considered here provide approximately twice as much product and increase maximum 
productivity even greater relative to the uncontrolled case. Since the maximum product 
concentration is achieved sooner in the controlled case, productivity (product concentra­
tion divided by elapsed operating time) is improved even more.
The degree of product accumulation improvement afforded by optimal switching of 
the amplification or expression time and the absolute value of the maximum product 
concentration achieved is a function of the final gene expression efficiency represented in
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the model by the parameter γf and the final plasmid content, Np,fmaι. By changing pro­
moter and ribosome binding site sequences and other aspects of the expression plasmid, 
the activity or "strength" of fully induced gene expression can be altered,8 corresponding 
to change in the model parameter γf. It is expected intuitively that stronger expression 
systems would have the direct benefit of increasing product synthesis rate but the indirect 
detriment of greater inhibition of normal cell metabolism and biosynthetic activity. 
Model simulations to explore the relationships among induced expression activity, time 
of expression induction, and the final product and productive fraction levels are summa­
rized in Fig. 3.6. Interestingly, for the kinetic and yield parameters employed in these 
calculations, there is an optimum combination of γf and îexp which greatly increases 
final product concentration.
Fig. 3.7 shows calculated results for product concentration at the end of the batch (at 
the time of substrate exhaustion) vs. the initiation time for amplification for several 
different Npιf⅛ιaι values. Also, product inhibition has been assumed negligible here (n=0 
in Eq. 2.3). The sharpness of the maximum in final product level is greatest for the 
largest Np,f⅛aι value considered. This maximum is less steep at an intermediate value of 
final copy number. However, here the maximum amount of product achievable is greater 
in absolute terms. The benefits of using a host-vector system providing environmental 
control of cloned-gene content is relatively less important in the case of low Npιfmaι. 
These results provide interesting insights into the interrelationship of host-plasmid pro­
duction strain construction, reactor operating strategies, and achievable production levels.
It is interesting to examine results of similar calculations for different situations as 
represented by different model parameters. First, the case of negligible inhibition of 
growth due to product accumulation has been considered (n=0 in Eq. 2.3). Here, 
choosing the optimal time for initiation of amplification at approximately 8 hrs. produces 
a much smaller increase in product concentration at the end of the batch than does
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the batch at high plasmid content characteristic of the fully amplified system 
(Np,fmai=50). If, on the other hand, the amplification involves attainment of higher 
plasmid content (the points for Npιfma]=90 in Fig. 3.7), the use of a switchable amplifîable 
system and optimal choice of the amplification time now provides substantial benefits 
relative to the reference case (Np=90 throughout the batch).
CONTINUOUS BIOREACTOR SIMULATION RESULTS
Staging of continuous reactors, operating at different conditions, can be used to mimic 
in a continuous process the effect of changing conditions with time in a batch process. 
This well-known relationship in chemical process engineering has been demonstrated 
experimentally by Siegel and Ryu for recombinant E. colil Using a cloned promoter 
induced by temperature shift, they studied a two-stage continuous flow stirred tank 
(CSTR) system in which a lower first tank temperature favored growth while higher 
second tank temperature induced gene expression. Since population growth does not 
occur under fully induced conditions,’ this two-stage arrangement, with the first tank 
providing an inoculant stream to the second, is essential for a successful process.
Using the intracellular simulation model previously described,7 the behavior of a more 
elaborate, three-tank process has been examined. Here, it is assumed that different 
controls on cloned gene expression induction (e.g., by adding inducer) and plasmid 
amplification (e.g., by temperature shift) allow independent manipulation of these two 
processes. It is assumed that both induction and amplification are off in the first CSTR, 
that the second CSTR conditions cause amplification (the plasmid copy number goes 
from 5 copies/cell to 50 copies/cell) and that cloned gene expression is induced (the 
expression parameter γ goes from 0 to 10) in the final CSTR of the three-reactor 
cascade. The total volume of the three reactors is maintained constant, and different alio-
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cations of this fixed capacity among growth, plasmid amplification, and gene expression 
are examined using model simulations.
Because of genetic instability, CSTR behavior in this case may be intrinsically 
dynamic; achievement of a steady state is not generally expected. Accordingly, model 
results are presented as time trajectories. Conditions at time zero are those at the end of a 
startup phase: tank 1 contains an inoculum based on previous batch growth (see Eq. 
2.36), and tanks 2 and 3 contain no cells. Fig. 3.8 shows the productive cell fraction and 
product concentration in the effluent from the third tank.
As expected the strategy of assigning equal residence times in all three chemostats is 
not an optimal one. Higher product concentrations in the effluent from the third CSTR 
can be achieved by distributing the residence times in a decreasing order; i.e., the pro­
ductive cells grow for longer time in an environment that does not favor gene amplifica­
tion and product formation. The substrate concentration in the effluent of the system, in 
the cases shown, drops to nearly zero after the system has been operating for a while (the 
time of substrate exhaustion is indicated by the breaks in the productive cell fraction vs. 
operating time curves). This means that practically all of the substrate being fed to the 
system is converted to biomass, and the total concentration of cells in the effluent is
constant.
The performance of the system depends on how the productive cell fraction is affected 
by the different distributions of residence times. Maximum growth rates of the two cell 
populations (productive and plasmid-free cells) are very similar when no product is pres­
ent and the plasmid copy number is kept low. By having larger residence times for the 
first stage, growth of the productive cells is favored (given that, at time zero, the concen­
tration of the plasmid-free cells in the first reactor is much lower than that of the produc­
tive ones). When the gene copy number is amplified, the difference on the maximum 
growth rates of the two populations widens, but again not as much as when product inhi­
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bition is introduced by cloned-gene expression. When finally product is first formed (in 
the last CSTR), the fraction of productive cells is high when the residence times have 
been distributed in a decreasing order, and product concentration in the effluent is 
increased compared with the equal-residence-times case. On the other hand, if the time 
spent in the third reactor becomes too small, increased effluent product concentration is 
not obtained (in the limit that the cells spend no time in the third reactor, the product 
concentration in the effluent will drop to zero).
Finally, the case of an increasing distribution of residence times in the three CSTRs is 
also shown, Both the product concentration and productive cell fraction are lower than 
for the equal-residence-times case. Such a distribution favors the plasmid-free cell popu­
lation, and, although the case shown does not result in total washout of the productive 
cells, this phenomenon, can also be observed for the different values of the dilution rates.
CONCLUSION
The trends evident in the simulations above are extremely reasonable on intuitive 
grounds and probably apply to host-vector systems quite different from those for which 
the model was formulated and with parameter values different from those considered. 
The more acute the negative influence of fully implemented gene expression on cell 
growth, the more useful it is to employ an origin of replication and/or cloned gene pro­
moter which permits environmental switching from low to high levels. Thus, to optimize 
a particular expression system with respect to these bioreactor operating variables, it is 
important to know the inhibition relationship among plasmid content, cloned-gene 
expression and product accumulation, and host-cell growth and protein synthesis.
The present model assumes reasonable trajectories for plasmid content and cloned- 
gene expression activity as a function of time since environmental switch. The results do
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reach the final copy number was changed from 2 hours to 4 hours since environmental 
switch, the difference in the final product concentration was less than 10% for the batch 
reactor case. If, however, the transient from the value characteristic of the original, 
growth-optimizing conditions and the final, product formation-optimizing conditions is 
substantially different and occurs over a much longer time scale, significant effects on the 
relationship between operating strategy and total product accumulation could result.
Only a limited and rather specialized class of environmental manipulations, a single 
switch was contemplated in this simulation study. More detailed optimization calcula­
tions allowing continuous trajectories of environmental conditions influencing gene 
amplification and expression levels is not deemed warranted until more detailed models 
are available, based upon experimental data, for cell growth inhibition and for the tran­
sients of gene expression efficiency and amplification. Given such information, it would 
be then interesting and worthwhile to explore the extent to which more sophisticated 
operating strategies and more finely tuned optimization calculations could further 
improve bioreactor performance.
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FIGURE 3.1: Diagram of the assumed trajectories for cellular plasmid content and gene 
expression parameter following a switch to environmental conditions promoting 
amplification and gene expression at time îamp or îexp, respectively.
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FIGURE 3.2: (A) Final cloned-gene product concentration (grains protein/liter culture) 
vs. the switching time (the time of plasmid amplification (o) and time of cloned- 
gene induction (∙)). (B) Fraction of cells containing plasmids after substrate ex­
haustion in the batch process as a function of initiation times for amplification (o) 









FIGÜRE 3.3: Illustration of product concentration at substrate exhaustion as a function 
of the time of amplification (îamp) and the time of expression (⅛χp) when both 
events can be activated independently at different points during batch operation. 
For the particular parameters considered here, maximum product accumulation is 























FIGURE 3.4: Final productive ce» fraction vs. atnpiiftcadon and expression switching 
times for batch operation. Same parameters as Fig. 3.3.
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FIGURE 3.5: Time trajectories (solid lines) of the productive cell fraction and cloned- 
gene product concentration vs. operating time in a batch reactor with tAMP=lθ, 
tEχp=lθ∙ Shown for comparison (dashed lines) are trajectories for the uncontrolled 
case with Np=50, γ=1.0.
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reactor.
FIGURE 3.6: Final product and productive cell fraction values for different induced 
gene expression activity values γ as a function of induction time teχp∙, batch
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FIGURE 3.7: Calculated final product concentration vs. amplification initiation switch­





































FIGURE 3.8: Simulated effluent product concentration and productive cell fraction for 
three different CSTR reactor cascades. Values are shown as functions of time 
since startup. Conditions in tanks 1,2, and 3 favor cell growth, cause plasmid 
amplification, and induce gene expression, respectively. Different symbols corre 
spond to different Vi:V2:V3 tank volume ratios, o=l :1:1; ·=1:1.5:3; Δ=3:1.5:1.
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CHAPTER 4




Regulation of many processes in the living cell, such as gene expression 
and DNA replication, are believed to be controlled by interactions of regulatory 
molecules with inducers, repressors, nucleic acid sequences, protein domains, and 
with each other. Mathematical models of these regulatory systems have been proven 
quite useful for quantitative description of cell population kinetic properties (see, 
for example, references 1-12). In most of these model calculations, the interactions 
have been assumed to be in equilibrium, and equilibrium concentrations have been 
calculated by assuming mass-action kinetics for complex formation and dissociation. 
This is equivalent to writing chemical potentials for the species involved in terms of 
their intracellular concentrations. As noted previously by Harder and Roels7 and 
others, the validity of this approach is questionable since the interactions considered 
actually occur in a collection of small closed systems, individual cells, each of which 
may contain a very small number of the molecules or binding sites involved in the 
control mechanism. On a single-cell basis, mass-action concepts which are based 
on properties of ensembles of large numbers of molecules are not applicable in any 
rigorous sense to species present in small numbers.
Binding states of such species exist only in discrete, limited numbers. For 
example, in a cell containing 10 molecules of species Sγ which can bind to some 
others species, the number of bound Sγ species molecules is 0,1,2,..., 8,9 or 10, 
and any of these binding states, and only one of them, would be observed if a single 
cell is examined at a particular point in time. Intracellular concentration of unbound 
species S± in this case is a discrete, not a continuous variable. The “equilibrium 
state” of a population of such cells refers to the average of the possible single-cell 
states weighted by the probabilities that the molecules are found in these states. 
These probabilities are properly calculated according to the methods of statistical 
thermodynamics.
The purpose of this paper is presentation of a general algorithm for cal­
culation of intracellular interaction equilibria in cell populations which is based on
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statistical thermodynamics appropriate to the small number of molecules - intracel­
lular situation. This algorithm is applied to a five-component model of regulation of 
transcription by the lac promoter-operator, and the results are compared to those 
based on the traditional single-cell equilibrium approach.
THERMODYNAMICS OF AN ENSEMBLE OF SMALL CLOSED
SYSTEMS
Consider a closed system consisting of n substances Sj, S2, ∙. ., Sn that can 
react with each other under ι independent reactions. Clearly 1 ≤ I ≤ n — 1. Let 
Py denote a state of the system:
Pj = (⅛S>,...,⅛) (4.1)
where S] denotes the number of molecules of substance S', in that state. For ex-t l
ample, states could denote unbound molecules and molecules complexed with other 
species. Now let Rrn denote one of the ι possible reactions:
Rn, = (^Γ,P2m,∙∙∙,^) (4∙2)
where ι∕n denotes the stoichiometric coefficient of substance Sl in reaction Rrn. 
Consider now Rm to be an operator acting on P1 defined as
(S,J + pjn, S⅜ + v™, ...,S}l + ι⅛l), when S,^ + i/£ > 0 ^θr everY
Rm{Pt∙} =
not defined when there exists a value of k such that ¾ ÷ p). < 0.
(4.3)
Then it is clear that the following identity holds:
Rm1 {Rm2 {Ri)} — Rm2{Rm1{Pt}} (4.4)
The equilibrium of the system depends on the equilibrium of a whole set 
of states P^ which are generated under the application of the possible reactions. 
Consider now two states,Py and Pt,that are related to each other with a reaction 
Rm ,i.e.
Fy — Rffi{P (4.5)
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Pj = (si + izΓ,SHp2"l,...,si + p-). (4.6)
Then the Gibbs free energy of the two states will be13:
¾=∑4∙4 (4-7)
fc=l
Gj = Σ (4 + <'Γ) ∙ 4 (4.8)
fc=l
where μ)c,μ⅛ are the chemical potentials (or the Gibbs free energy per molecule) of 
the substance S∣ι in the two states. These chemical potentials are given by:











where V is the volume of the system, k is the Boltzmann’s constant, T is the system’s 
temperature, and μθ is the standard chemical potential of S∣ς. Then, substituting 
eqn. (4.9-10) into eqn. (4.7-8),
<?i = Σ 4'4 +*Γ ∙'n(∏ (sj)!) - kT ■ (∑ Sik)lnV
k=l k=l k=l
g, = ∑(si + 4C) ∙⅛ + fcr-⅛(∏(4 + ⅛m)') - kT
k=l k=l





- ÎT ■(£>?·) ZnV. 
k=l
(4.13)
The first term of the right part of the above equation 
change in the free energy for the standard reaction Rrn 
modynamics. Accordingly,
is easily recognized as the 
is defined in classical ther-
ΣS lzΓ∕zθ - &Gm
fc=l
= —kT ■ lnKm
(4.14)
where Km is the equilibrium constant of the Rm reaction. If we denote now Gτ to
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be G,jJkT, equation (4.13) becomes
Gj = Gi - lnKm + InI⅛1(¾ + ιT)!
fc=l
(4.15)
This result indicates that the Gibbs free energy of a state may be calculated knowing 
only the properties of its “parental” or predecessor state, and reaction data.
The overall Gibbs free energy of the closed system is:
TV λ N
G =∑Pi∙Gi + ∑pi∙lnpi. (4.16)
t=l i=l
where N is the total number of states in the system and pl is the probability of 
existence of state Pt. The equilibrium state of a large ensemble of such closed 
systems is characterized by probabilities pt such that G is minimized. In such a 
population, pi has the alternative physical interpretation as the expected fraction of 
the population in state Pi. Thus, the values of the probabilities p, which minimize 
G must be determined subject to the constraint
Pl + P2 + ∙ ∙ ∙ + PN - 1








The choice of the state to be named P^ is arbitrary. If Pj is taken to be the state 
that, under the action of reactions Rrn, does not have any “parental” states (i.e., no 
other states are transformed to P1 under the action of any of the reactions), then 
Grj can be assigned an arbitrary value. This is allowed since with Pi so defined, 
every possible state of the system has, either explicitly (eqn. 4.3) or implicitly (eqn. 
4.4), Pi as its “parental” state, and so G] has been added to every state’s free 
energy (eqn. 4.15).
Finally, the average concentration, S⅛, of the various substances in the pop-
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ulation at equilibrium can be calculated as1,14:
N
Sk=∑ Pi ■ S,k (4.20)
y=ι
APPLICATION TO THE lac REPRESSOR-OPERATOR SYSTEM
The lac repressor-operator system can be described by the following set of 
reactions11,12:
R + O^∙ RO K1 = 2 × 1012 M~1
R + I≠RI K2 = 1 × 107 M~1
RI + O≠ RIO Tf3 = 2 × 109 M^1
R -)- D^ς^ RD K4 = 1 × 103 M~1
RI + D≠ RID K5 = 1.5 × 104 M~1
where R denotes the lac repressor protein, O the lac operator, I the lac inducer 
(isopropyl-/?-D-thiogalactopyranoside; IPTG), D the nonspecific binding sites (the 
entire genome), RO, RI, RIO, RD, RID the corresponding complexes, and Km 
are the corresponding association constants.
At this point, is highly convenient to eliminate the reactions involving non­
specific binding sites, because the high value of Dq (the total number of nonspecific 
binding sites ≈ 107 sites/cell) will otherwise lead to a numerical instability in the 
calculations. The elimination of the nonspecific binding of the lac repressor is a 
commonly used technique in work done on the subject15,16, but the additional com­
plexity of the binding of RI to nonspecific binding sites is included in the model. 
The equivalent reduced system involves only the first three reactions and modified 
effective association constants as listed below (this reduction, although based on 
use of classical equilibrium relations, is justified by the high concentration of Dq 
which has physical meaning):
K, =
1 1 + k4d0
, = 7<2(1+A5Po)






According to the previously introduced notation, n
(4.23)
6, I = 3 for this case
and
(S1,S2,S3,S4,S5,S6) ≡ (R,O,I,RO,RI,RIO)
R1 = (-l,-l, 0, 1, 0, 0)
R2 = (-1, 0,-l, 0, 1, 0)
R3 = (0,-l, 0, 0,-l, 1)
A suitable P4 state for this system is of the form:
Pi == (-Ro>Oo,∕o>°>θ>0)
The results of the simulation for P4 = (10,1, Iq,0, 0,0) and P4 = (10,15, Iq, 0,0,0), 
for Iq varying from 0 molecules/cell to 10,000 molecules/cell (≈ 2 × 10-5 M), are 
shown in Figures 4.1 and 4.2.
The lac repressor-operator system is mainly characterized by the ratio of 
free specific binding sites to total specific binding sites. Figure 4.3 shows the error 
in calculating this ratio by the traditional intracellular equilibrium relations versus 
the (total) inducer concentration. These results show errors are greatest at low 
inducer concentrations and approach zero as inducer concentration increases. The 
same trends hold with respect to effects of the number of operator sites on this 
error (larger errors when fewer operator sites are present). The exception to this 
pattern occurs when no inducer is present. Then, the error is maximized when the 
operator sites are equal to the lac repressor molecules present in the cell.
For practical situations the error introduced by application of the traditional 
single-cell equilibrium forms is less than 10%. This leads to the conclusion that the 
mass-action law is a valid approximation in cell modeling (at least in the case 
of the lac operon) since the errors involved can be considered of the same order of 
magnitude as the errors and uncertainties incorporated in other steps. For example, 
the equilibrium constants that were used in this work had been reported in the 
literature within an order of magnitude, which introduces an uncertainty of at 
least 5-10% in calculated results. Also, deviations from other assumptions in these
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calculations - such as the existence of equilibrium conditions in the cell - may cause 
similar deviations between model and experiment.
From the practical point of view, the proposed algorithm requires much more 
computing time than the algorithm for solving the nonlinear algebraic system in­
duced by the traditional single-cell equilibrium equations and mass balances (where 
required in this work a simple contraction method was used for the traditional ap­
proach, and quadratic convergence was always the case). Futhermore, the statistical 
method can result in numerical instabilities when too many states, that range from 
highly probable to almost improbable, are examined (a state selection is required 
then). It is likely that the simpler single-cell equilibrium approach is an adequate 
approximation in most cases and therefore preferable. When doubts arise as to 
the extent of the error introduced by this approximation, the algorithm presented 
here can be used to effect more accurate calculations for cell populations containing 
small numbers of interacting molecules.




D Non specific binding sites for the lac repressor




∕Q Equilibrium constant for reaction i
ι Total number of reactions
n Total number of substances
O lac operator
pt Probability of existence of a state i
Pj Representation “vector” of state i
R lac repressor protein
Rj Representation “vector” of reaction i
Si Substance i
S- Number of molecules of substance i in state jz *f
Sl Average number of molecules of substance i in the system 
T Temperature of the system
V Volume of the system
Greek Letters.
μ-,ι Chemical potential of substance i in state j
μ® Standard chemical potential of substance i
ι/'? Stoichiometric coefficient of substance i in reaction i z *f
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TOTΔL INDUCER LEVEL [I]c 
(x I04 molecules/cell)
FIGURE 4.1: The results of the statistical (points) and the traditional (lines) approaches 



























TOTΔL INDUCER LEVEL [l]0 
(x IO4 molecules/cell)
FIGURE 4.2: Equilibrium concentrations calculated for the lac repressor-operator sys­
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FIGURE 4.3: The relative error [(Otrad-Ostat)∕Ostat] associated with the use of the tradi­




KEY FEATURES OF THE DATA BASES AND PATHWAY 
SYNTHESIS PROGRAMS OF MPS
-105-
1 DESCRIPTION OF THE DATA BASES
There are two data bases used by the program, one for enzymes and one for sub­
stances. Both data bases implement structures for storing information.
1.1 The Enzyme Data Base
The general representation for an enzyme in the data base is given in Figure Al. 
The description of the various fields is given in Table Al.
The fields that are actually used by the search algorithm are the “reaction” and 
“reversible” fields. The rest of the fields do not affect the progress of the search 
algorithm but merely provide either additional information about the enzyme (such 
as the “coupling reaction” field) or ways of calling up sets of pathways that fulfill 
some desired property. For example, the user may want to identify the subset of 
the synthesized pathways that contain at least one enzyme inhibited by ATP.
The characterization of reactions as reversible or irreversible under physiological 
conditions is based on information reported in standard biochemistry books. An 
alternative examined was to introduce in that field the standard Gibbs free energy 
change, ΔG0', of the reaction. Lack of data on the intracellular concentrations of 
the majority of intermedates is then a major problem. In order for a reaction to be 
characterized as reversible or not, the value of the Gibbs free energy change, ΔG, is 
required. ΔG can be calculated, given ΔG°,, only when the concentrations of both 
reactants and products are known. For example consider the reaction:
fructose 1,6-diP ÷=i dihydroxyacetone-P + glycera,ldehyde 3-P
for which ΔG0' = +5.7 kcal/mol, a value high enough to assume that this reaction 
occurs only in the reverse direction under standard conditions (ΔG = ΔG0'). Un­
der physiological conditions, however, ΔG = —0.3 kcal/mol, so this reaction is
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reversible in the cellular environment. Since the intracellular concentrations cannot 
be calculated or measured for the majority of metabolic intermediates, the value 
of ΔG°, provides less information than the a priori characterization of a reaction 
as reversible or irreversible. When in doubt, a reaction can be characterized as 
reversible (at the expense of increased execution time), and possible scenarios of 
the form: “What if this reaction proceeds in only one direction?” can be examined 
after the search has been completed.
The “coupled-reaction” field serves the role of distinguishing between “impor­
tant” and “non-important” substances in the reaction, from the point of view of 
the search algorithm. Consider for example glycolysis. Cofactors, such as ATP and 
NAD(P)H, are used or consumed by the glycolytic pathways. In order to max­
imize the efficiency of MPS for biotransformations, the search algorithm should 
not be concerned with the problem of how these cofactors are synthesized and 
how the cofactors can be converted to the target products. Instead, the algorithm 
should be focused on the carbon-carrying intermediates (except CO2). Thus, ATP, 
NAD(P)H, etc., are “non-important” reactants or products of the glycolytic path­
ways. The same does not hold when other areas of the metabolic network are 
considered. For an enzyme that belongs to the ATP biosynthetic paths, ATP is 
considered an “important” substance. This distinction between “important” and 
“non-important” substances is not always clear or possible, as, for example, in the 
case of a transamination reaction. Then, all the substances participating in the 
reaction are considered “important” (at the expense of higher execution time).
The representations of two enzymes stored in the data base are shown in Fig­
ure A2. The enzyme homoserine acyliransferase, (EC2.3.1.3l), which is tradition­
ally classified in the aminoacid biosynthetic pathways, catalyzes the irreversible 
reaction:
succinyl-CoA + L-homoserine → CoA + O-succinyl-homoserine
and is inhibited by methionine. The enzyme phosphogîyceromutase, (EC2.7.5.3),
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which is traditionally classified in the EMP pathway, catalyzes the reversible reac­
tion:
3-P-glycerate + 2,3-diP-glycerate τ± 2,3-diP-glycerate + 2-P-glycerate
and does not have any inhibitors or activators.
1.2 The Substance Data Base
The substance data base is supportive for the enzyme data base and the search 
algorithm. For the representation of substances analogous data structures as the 
ones used for enzyme descriptions were used. The fields defined for substance de­
scriptions are identified in Table A2.
The formal name of the substance is used by the program to refer to this sub­
stance during output. The user may refer to a substance by its formal name, or by 
any of its synonyms or pseudonyms. For example, although the program will always 
refer to glyceraldehyde 3-phosphate by using the formal name, the user may refer 
to it as “GA3P” when running the program or building an enzyme data-base. The 
“carrier” field contains the chemical elements that this substance carries through 
the metabolic network. Finally, the two last fields, which are characterized as in­
ternal in Table A2, are calculated by MPS. In Figure A3, the representations of 
3-phospho-D-glyceroyl phosphate and O-phospho-L-homoserine are shown.
2 MPS: THE PROGRAM
2.1 Initialization
The first thing that MPS does is read the substance and enzyme data base. The 
user is asked for the name of these files, so enzymatic activities and substance 
descriptions can be organized in multiple data bases for particular metabolic proc­
esses or particular organisms, for example. However, since the program checks for 
unidentified substances, i.e. substances that are referenced in the enzyme data base 
but are not described in the substance data base, it is important that the enzyme
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and substance data bases are compatible. Alternatively, all substance descriptions 
may be contained in a common data base used by every enzyme data base. The 
drawback of such an approach is that if, for example, a small enzyme data base is 
used for studying just the pathways for ethanol production in a microorganism, the 
full set of substances, whether relevant to the enzymes loaded or not (such as the 
intermediates for amino acid biosynthesis, for example), will be loaded and occupy 
memory without being needed.
2.2 The Search Algorithm
A search problem is described by an initial state, a goal defining set of criteria 
that the target state should satisfy, and a set of rules or operators that define the 
transformation of a given state to another. Consider, for example, the network 
shown in Figure A4. Assume that S is the initial state of the search problem. The 
operators are the lines connecting two nodes (e.g., L and M) of the network. Then a 
possible scenario for the search problem can be “What are the final states which can 
be produced starting from S'?”. A final state is defined by the following property: 
any further application of the operators on the final state produces successor states 
which were already considered as parental states. In this version of the search 
problem, the “products” of a state are accorded primary emphasis. Most of the 
time, however, the produced states are equally important as the ways (paths) that 
were used to produce them. Consider, for example, a more restrictive goal-defining 
criterion: “Generate F”. One possible path solving this problem is traced in bold 
lines in Figure A4. It is described as a set of intermediate states connecting S to F. 
It is obvious that the answer (SOPF) is not the only one that can be derived from 
this network. Other paths also exist. If each rule of transformation was assigned a 
“cost” then the goal criterion could have been formulated as “Generate the path to 
F that is optimal; i.e., minimizes the overall cost of the transformation.”
So far the description of a search network (or search space) was based on a 
description of states. The underlying information in Figure A4 is the description of
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the transformation rules. The corresponding operators are listed in Table A3. The 
search problem in this case is defined as “Starting from a rule that transforms S, 
(either E1 or E2), end up with a rule that produces F (one of E7, Eg, Eg).” The 
solution, (i?2, Eg, E7}, is traced in bold lines in Figure A4.
The metabolic network can be viewed as a collection of operators, i.e., enzymes. 
Each enzyme catalyzes a reaction that can be viewed as a transformation of the 
substrate state to the product state. The metabolic network, however, is more 
complex that the picture already given. After starting from a substrate, say A, 
and extending a pathway, eventually an enzyme will be considered that requires 
multiple substrates. Consider the case in Figure A5. In order for the enzyme E3 to 
be incorporated in the path (Ei E2), not only C must be produced, but Y as well. 
Moreover the stoichiometric ratio of C to Y is fixed by the reaction description 
of Es. If Y can be produced from A, say by a single reaction catalyzed by E4 in 
Figure A5, then Eα can be used, and the path extension will continue. Otherwise, 
the path will be abandoned.
Another “peculiarity” of metabolic reaction network synthesis is introduced 
when substances that have been consumed at some part of the pathway are re­
generated later. Consider the case shown in Figure A6. In order for the enzyme Eg 
to be incorporated in the extending pathway, a pathway from A to E has been added 
and this pathway consumed D. After the reaction catalyzed by Eg was added to the 
pathway, however, D has been synthesized. That means that it was not necessary 
to produce D directly from A in the first case. This has to be considered by the 
search algorithm. Before further elongation of the pathway takes place, the trans­
formation shown in Figure A6 must take place. This transformation is not always 
possible considering the stoichiometric requirements of the participating enzymes, 
in which case it is not carried out by MPS.
The design of MPS’s search algorithm is such that if the target product has been 
reached and carbon-containing side products have also been formed, then the search 
continues in order to convert the side products to the target substance. This is not
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always possible. In any case, the first time that the target product is encountered 
in a pathway is always reported, while the subsequent steps are recorded only in 
the case that there is successful conversion of the side products to the end product. 
For example consider the following set of reactions:
Ei : A → B + C
E2 : C → F
e3-. B → D
E<∙. D → E + F
e5-. E → F






(Eι l)(E2 1) A→ F + B
(Eι 1)(E3 l}(Ei 1) A→ F+C + E
(Eι 1)(E2 l)(P3 l)(P4 1) A → E + 2F
(Eι l)(E3 1)(E4 1)(Γ5 1) A→2F + C
(Eι 1)(E2 l)(P3 1)(P4 1)(P5 1) A→3F
Note that the pathway P ≡ (E1 l)(F,2 l)(P3 l) with overall reaction A → D + F is 
not reported, since it includes pathway Pi and requires additional enzymes without 
eliminating by-product formation.
A major restriction must be imposed in order to obtain independent pathways 
from MPS’s search algorithm: if an enzyme requires a substrate already used by the 
pathway to that enzyme, then this substance must be produced by the same set of 
enzymes used in the pathway. To illustrate this restriction, consider the following 
network:
Ei : A → B
e2-. A → C
E3 : B → c
Ei : C → D
E, : C + D → F
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How many independent ways exist for the conversion of A to FI There are two 
ways of producing C:
P1 ≡ (E1 1)(P3 1) A→C 
P2 ≡ (E21) A→C
and so, there are two ways of producing D:
P[ = {E1 l)(Es l)(P4 1) A→D 
P'2 ≡ (E2 l)(E4 1) A→D
Eζ requires both C and D as substrates. So in order Eb to be incorporated in a 
pathway, pathways producing both C and D have to be combined. The possible 
combinations are (P1, P1'), (P1, Pj), (P2, P[), (P2, Pj), and the resulting pathways 
are:
Pα ≡ (E1 2)(P3 2)(P4 1)(P5 1) A→F
Pb ≡ (E1 l)(P2 1)(P3 1)(P4 1)(P5 1) A → F
Pc ≡ (P1 1)(P2 1)(P3 1)(P4 1)(P5 1) A → F
pd ≡ (E2 2)(E4 1)(P5 1) A→F
These pathways are not linearly independent, since P⅛ = Pc, and Pb — 0.5Pα + 0.5Pd. 
How about genetic independence, i.e., do Pα, P⅛, Pc, Pi define independent sets of 
enzymes? Clearly P⅛ and Pc do not since they are identical. Moreover, an organism 
that uses the pathway P⅛ also has the necessary enzymatic activity to carry out both 
Pa and Pi. That means that there are just two genetically independent pathways 
for transforming A to F, and MPS, by applying the restriction that substrates have 
to be generated in the same way throughout a pathway, will report just Pa and Pi.
The rules mentioned are part of the design of MPS’s search algorithm. They 
have been gradually introduced in the program in order to achieve efficient manage­
ment and processing handling of a large data base. Their purpose is to eliminate in 
early stages the combinatorial effect of having pathways constructed by just putting 
enzymes together. By searching for the independent pathways, instead for searching 
for all pathways and then extracting the minimum set of pathways that character­
ize the conversion, both memory and execution time requirements are drastically
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reduced. If in the last example there were N pathways transforming A to C and 
one pathway transforming C to D, then, by not incorporating the rule that is used 
by MPS for this case, enough memory would need to be allocated to allow the al­
gorithm to handle N × N pathways. By adopting the rule, on the other hand, N 
pathways are tracked from the beginning of the search.
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FIELD DESCRIPTION
Code The EC number of the enzyme as it appears in Enzyme 
Nomenclature.
Name The name of the enzyme. It can either be the one recom­
mended by the Nomenclature Committee of the Inter­
national Union of Biochemistry, or the systematic name 
based on the reaction catalyzed.
Reaction The reaction catalyzed by the enzyme. In this field only 
the substances associated with the search algorithm ap­
pear.
Reversible If the reaction catalyzed is reversible under physiological 
conditions, then T appears in this field; otherwise, NIL 
appears.
Coupling-Reaction The reaction coupled to the main reaction, involving 
substances that should not be involved in the search.
Inhibited-by Reported inhibitors of the enzyme.
Activated-by Reported activators of the enzyme.
Pathways The pathways in which the enzyme is traditionally clas­
sified.
TABLE Al: The fields used for enzyme descriptions.
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FIELD DESCRIPTION
Name The formal name of the substance.
AKA Other names or pseudonyms of the substance.




Enzyme nodes that use this substance as a substrate.
Produced-by
(internal)
Enzymes nodes that produce this substance.
TABLE A2: The fields used for substance descriptions.
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Name Rule
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"HOMOSERINE ACYL TRANSFERASE’ 





















FIGURE A2: The representation of homoserine acyltransferase and phosphoglycero-














CARRIER (C P N))
FIGURE A3: The representation of 3-phospho-D-glyceroyl phosphate and O-phospho
L-homoserine in the substance data base.
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FIGURE A4: A simple search network.
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FIGURE A5: Reaction networks incorporate multiple linear pathways in order to pro 
vide the necessary substances for reactions requiring more than one reactant.
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Ω>
FIGLJRE A6: Reaction networks incorporate cyclic pathways when substances that have
been already consumed are regenerated.
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APPENDIX B
THE ENZYME DATA BASE USED TO OBTAIN 







































































































#s(ΕΝΖΥΜΕ : CODE (2723)
: NAME "PHOSPHOGLYCERATE KINASE"
: REACTION (("3-PHOSPHO-D-GLYCEROYL PHOSPHATE 
("3-PHOSPHO-D-GLYCERATE" 1))
.•REVERSIBLE T





#s(ENZYME : CODE (2753)
: NAME "PHOSPHOGLYCEROMUTASE"
: REACTION (("3-PHOSPHO-D-GLYCERATE" -1)
("2-PHOSPHO-D-GLYCERATE" 1))
: REVERSIBLE T





#s(ENZYME : CODE (421 11)
: NAME "ENOLASE"
: REACTION (("2-PHOSPHO-D-GLYCERATE" -1)
("PHOSPHOENOLPYRUVATE" 1))
•.REVERSIBLE T




#s(ENZYME : CODE (271 40)
: NAME "PYRUVATE KINASE"
: REACTION (("PHOSPHOENOLPYRUVATE" -1) 
("PYRUVATE" 1))
: REVERSIBLE NIL






: NAME "PYRUVATE DEHYDROGENASE COMPLEX"
: REACTION (("PYRUVATE" -1)
("ACETYL-CoA" 1))
: REVERSIBLE NIL








































































































: COUPLING-REACTION (("GTP" -1)
("CoA" -1)
("GDP" 1)




#s(ΕΝΖΥΜΕ : CODE (1 3 99 1)
: NAME "SUCCINATE DEHYDROGENASE"
: REACTION (("SUCCINATE" -1)
("FUMARATE" 1))
: REVERSIBLE T





#s(ENZYME : CODE '(4 212)
: NAME "FUMARATE HYDRATASE"
: REACTION (("L-MALATE" -1)
("FUMARATE" 1))
: REVERSIBLE T




#s(ENZYME : CODE (111 37)
•.NAME "MALATE DEHYDROGENASE (1 1 1 37)
: REACTION (("L-MALATE" -1)
("OXALOACETATE" 1))
: REVERSIBLE T





#s(ENZYME : CODE (4138)
: NAME "ATP-CITRATE LYASE"












: NAME "PYRUVATE CARBOXYLASE"












#S(ENZYME : CODE (111 40)
: NAME "MALATE DEHYDROGENASE (1 1 1 40)"
: REACTION (("L-MALATE" -1)
("PYRUVATE" 1))
•.REVERSIBLE T






#s(ENZYME : CODE (4131)
: NAME "ISOCITRATE LYASE"




: COUPLING-REACTION ( )
:INHIBITED-BY ( )
: ACTIVATED-BY ( )
: PATHWAYS ("GOC"))
#s(ENZYME : CODE (4132)
:NAME "MALATE SYNTHASE"









#s(ENZYME : CODE (111 49)
: NAME "GLUCOSE-6-PHOSPHATE DEHYDROGENASE
: REACTION (("D-GLUCOSE 6-PHOSPHATE" -1)
( "D-GLUCONO-<3-LACTONE 6-PHOSPHATE
: REVERSIBLE NIL




















#S(ENZYME : CODE (421 12)
: NAME "PHOSPHOGLUCONATE DEHYDRATASE"
: REACTION (("6-PHOSPHO-D-GLUCONATE" -1)
("6-PHOSPHO-2-KETO-3-DEOXY-D-GLUCONATE
: REVERSIBLE NIL




#S(ENZYME : CODE (111 44)
: NAME "PHOSPHOGLUCONATE DEHYDROGENASE"
: REACTION (("6-PHOSPHO-D-GLUCONATE" -1) 
("D-RIBULOSE 5-PHOSPHATE" 1))
: REVERSIBLE NIL




: ACTIVATED-BY ( )
: PATHWAYS ("PHP"))
#s(ENZYME : CODE (5131)
: NAME "RIBULOSEPHOSPHATE 3-EPIMERASE"
•.REACTION (("D-RIBULOSE 5-PHOSPHATE" -1) 
("D-XYLULOSE 5-PHOSPHATE" 1)).
: REVERSIBLE T




(fs(ENZYME : CODE (5316)
: NAME "RIBOSEPHOSPHATE ISOMERASE"




∙. INHIBITED-BY ( )
-.ACTIVATED-BY ( )
: PATHWAYS ("PHP" ) )
#s(ENZYME :CODE (2211)
: NAME "TRANSKETOLASE-1"
: REACTION (("SEDOHEPTULOSE 7~PHOSPHATE" -1)









#s(ΕΝΖΥΜΕ : CODE (2212)
: NAME "TRANSALDOLASE"









#s(ENZYME : CODE (2211)
: NAME "TRANSKETOLASE-2"
: REACTION (("D-XYLULOSE 5-PHOSPHATE" -1) 
("D-ERYTHROSE 4~PHOSPHATE" ~1) 







#s(ENZYME : CODE (412 14)
: NAME "PHOSPHO-2-KETO-3-DEOXY-GLUCONATE ALDOLAS








#s(ENZYME : CODE (1414)
: NAME "L-GLUTAMATE DEHYDROGENASE (NADP+)"
: REACTION (("L-GLUTAMATE" -1)
("2-OXOGLUTARATE" 1))
.•REVERSIBLE T







#s(ENZYME : CODE (6312)
: NAME "GLUTAMINE SYNTHETASE"
: REACTION (("L-GLUTAMATE" -1)
("L-GLUTAMINE" 1))
: REVERSIBLE NIL




















































































































































































































































































































#S(ENZYME : CODE (111 81)
: NAME "HYDROXYPYRUVATE REDUCTASE"
: REACTION (("D-GLYCERATE" -1)
("HYDROXYPYRUVATE" 1))
: REVERSIBLE T





#S(ENZYME : CODE (2 6 1 45)
: NAME "SERINE-GLYOXYLATE AMINOTRANSFERASE









#s(ENZYME : CODE (261 51)
: NAME "SERINE-PYRUVATE AMINOTRANSFERASE"









#s(ENZYME : CODE (2121)
: NAME "SERINE HYDROXYMETHYLTRANSFERASE"
: REACTION (("GLYCINE" -1)
("L-SERINE" 1))
: REVERSIBLE T






#s(ENZYME :CODE (231 30)
.•NAME "SERINE ACETYLTRANSFERASE"














: CODE , (9993)
: NAME ’’CYSTEINE SYNTHASE"








: CODE (231 31)
: NAME "HOMOSERINE ACYLTRANSFERASE"








: CODE (4 2 99 9)
: NAME "O-SUCCINYLHOMOSERINE(THIOL)-LYASE"










: NAME "CYSTATHIONINE fc>-LYASE"









: CODE (211 10)
: NAME " HOMOCYSTEINE-.N5-METHYLTETRAHYDROFOLATE
: REACTION (("HOMOCYSTEINE" -1)
("METHIONINE" 1))
: REVERSIBLE T






#s(ΕΝΖΥΜΕ : CODE (4 2 99 11)
••NAME "METHYLGLYOXAL SYNTHASE"
: REACTION ( (''DIHYDROXYACETONE PHOSPHATE" -1) 
("METHYLGLYOXAL" 1))
: REVERSIBLE T
: COUPLING-REACTION (("PHOSPHATE" 1))
:INHIBITED-BY ( )
:ACTIVATED-BY ()
: PATHWAYS ("METHYLGLYOXAL BYPASS"))
#s(ENZYME : CODE ((4 4 1 5) (3 1 2 6))
:NAME "GLYOXYLASE I, II"
: REACTION (("METHYLGLYOXAL" -1)
("D-LACTATE" 1))
: REVERSIBLE T
: COUPLING-REACTION (("H2O" -1))
:INHIBITED-BY ()
:ACTIVATED-BY ()
: PATHWAYS ("METHYLGLYOXAL BYPASS"))
#s(ENZYME : CODE (1123)
: NAME "LACTATE DEHYDROGENASE (CYTOCHROME)
: REACTION (("D-LACTATE” -1)
("PYRUVATE" 1))
: REVERSIBLE T




: PATHWAYS ("METHYLGLYOXAL BYPASS"))
